celecoxib and Osteoarthritis studies

Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.

Research Excerpts

Excerpt	Relevance	Reference
"NAXOZOL was not inferior to celecoxib in protecting the gastrointestinal tract and providing pain relief in patients with osteoarthritis."	9.34	A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis. ( Kang, CN; Kim, HJ; Kim, JH; Lee, S; Lee, WS; Moon, SH; Park, MS; Shin, SJ, 2020)
"Samples were from a randomized, parallel, double-blind trial of pharmaceutical grade 1500 mg GH + 1200 mg CS (n=96) versus 200 mg celecoxib daily (n=93) for 6- months in knee osteoarthritis (OA) patients."	9.34	Differences in Serum Biomarkers Between Combined Glucosamine and Chondroitin Versus Celecoxib in a Randomized, Double-blind Trial in Osteoarthritis Patients. ( Herrero, M; Ladd, J; Lampe, JW; Lampe, PD; Lo, E; Martinez, H; Navarro, SL; Randolph, TW; Shelley, D; Zhang, Y, 2020)
"To describe utilization patterns of duloxetine and celecoxib and subsequent opioid use among patients with osteoarthritis."	9.17	Utilization of duloxetine and celecoxib in osteoarthritis patients. ( Andrews, JS; Chen, SY; Novick, D; Peng, X; Wu, N; Yu, X, 2013)
" Omeprazole and Diclofenac for At-Risk Osteoarthritis and Rheumatoid Arthritis Patients (CONDOR) trial showed that a haemoglobin drop ≥2 g/dL adjudicated as either of defined or presumed GI origin was the most frequent component/event for the composite GI primary end point."	9.16	Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). ( Chan, FK; Goldstein, JL; Lanas, A; Li, C; Peura, DA; Sands, GH; Scheiman, JM; Wilcox, CM, 2012)
"To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors."	9.14	Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010)
"The SF-36 Quality of Life questionnaire was used in this prospective multicenter study to evaluate changes in pain intensity and quality of life in 2339 patients with osteoarthritis treated by 1244 general practitioners with celecoxib (200 mg per day) for 4 weeks."	9.13	[Changes in quality of life in patients with osteoarthritis treated with celecoxib: the Qualice study]. ( Jeanpetit, Y; Méric, G; Rozenberg, S, 2008)
"Randomized clinical trials evaluating ultramicronised diclofenac, diclofenac, celecoxib, etodolac and placebo in patients with osteoarthritis were identified."	9.12	Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis. ( Auletta, LL; de Almeida Macedo, E; de Campos, GC; Kummer, AM; Millan Fachi, M; Papaleo Rosim, M, 2021)
"We included randomized controlled trials of oral celecoxib compared with a non-selective NSAID or placebo in rheumatoid arthritis and osteoarthritis patients."	9.12	Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis. ( Chen, JQ; Cheng, BR; Gao, QY; Li, WH; Liu, JP; Wu, CJ; Xing, JL; Yan, LJ; Zhang, XW; Zhang, YQ, 2021)
"To compare the lower osteoarthritis (OA) dose of rofecoxib to the recommended dose of celecoxib in two identically designed studies."	9.12	Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. ( Birbara, C; Chang, DJ; Petruschke, RA; Rodgers, A; Ruoff, G; Sheldon, E; Tershakovec, AM; Valenzuela, C, 2006)
"To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis."	9.12	Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. ( Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C, 2006)
"To assess the use of n-of-1 trials for short-term choice of drugs for osteoarthritis, with particular reference to comparing the efficacy of sustained-release [SR] paracetamol with celecoxib in individual patients."	9.12	Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. ( Brown, RM; Del Mar, CB; McNairn, N; Nikles, CJ; Schluter, PJ; Yelland, MJ, 2007)
"To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare."	9.12	A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. ( De Clerck, L; De Keyser, F; Geusens, P; Hauzeur, JP; Luyten, FP; Malaise, M; Mathy, L; Raeman, F; Van den Bosch, F; Vander Mijnsbrugge, D; Westhovens, R, 2007)
"To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies."	9.12	Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. ( Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM, 2007)
"We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease."	9.12	Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006)
"5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)."	9.11	Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004)
"In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd."	9.11	Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004)
"To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)."	9.11	Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005)
" This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens."	9.10	Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002)
"An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment."	9.10	Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003)
"The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect."	9.10	A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003)
"To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability."	9.10	Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002)
"To evaluate the functional status of patients with signs and symptoms of osteoarthritis of the knee after treatment with celecoxib compared with placebo and naproxen."	9.09	Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. ( Dedhiya, SD; Markenson, JA; McMillen, JI; Osterhaus, JT; Yu, SS; Zhao, SZ; Zhao, WW, 1999)
"To compare the efficacy and safety of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, with those of naproxen, a nonsteroidal anti-inflammatory drug (NSAID), and placebo in the treatment of osteoarthritis of the knee."	9.09	Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. ( Bensen, WG; Fiechtner, JJ; Geis, GS; Hubbard, RC; Isakson, PC; McMillen, JI; Verburg, KM; Woods, EM; Yu, SS; Zhao, WW, 1999)
"The US Food and Drug Administration recently granted an approved indication for the first fixed-dose combination antihypertensive (amlodipine) and nonsteroidal anti-inflammatory drug (celecoxib) for treatment of comorbid hypertension and osteoarthritis."	9.01	Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. ( Cooper-DeHoff, RM; Smith, SM, 2019)
"This study aimed to assess the relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen at recommended dosages in patients with osteoarthritis (OA)."	8.93	Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. ( Choi, SJ; Ji, JD; Kim, JH; Lee, YH; Seo, YH; Song, GG, 2016)
"The efficacy of celecoxib as an analgesic was comparable to that of loxoprofen, whereas serious GI events, including symptomatic ulcers, were significantly less frequent with celecoxib than with loxoprofen in Japanese patients with rheumatoid arthritis (RA) and osteoarthritis (OA) (p = 0."	8.87	Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. ( Sakamoto, C; Soen, S, 2011)
"The objective was to improve understanding of adverse events occurring with celecoxib in the treatment of osteoarthritis and rheumatoid arthritis."	8.82	Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. ( Derry, S; Makinson, GT; McQuay, HJ; Moore, RA, 2005)
"To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 (COX 2) inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis."	8.81	Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. ( Bradley, MD; Deeks, JJ; Smith, LA, 2002)
" Celecoxib, an anti-inflammatory and analgesic agent indicated for the treatment of osteoarthritis and rheumatoid arthritis, is the first cyclooxygenase (COX) inhibitor with well-defined cyclooxygenase-2 (COX-2) specificity."	8.80	Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. ( Tindall, E, 1999)
"Celecoxib is the first COX-2 specific inhibitor approved for use in osteoarthritis and rheumatoid arthritis."	8.80	Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. ( Clemett, D; Goa, KL, 2000)
"This paper aims at demonstrating silk fibroin nanoparticles (SFNs) promote anti-inflammatory properties of celecoxib (CXB) or curcumin (CUR), and could be exploited for osteoarthritis (OA) treatment."	7.91	Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis. ( Bari, E; Catenacci, L; Crivelli, B; Faragò, S; Mocchi, M; Perteghella, S; Prina-Mello, A; Sorrenti, M; Torre, ML; Tripodo, G, 2019)
"A prospective, 3-year comparative observational study compared the risk of cardiovascular events in patients with osteoarthritis or rheumatoid arthritis prescribed celecoxib or a nonsteroidal antiinflammatory drug (NSAID)."	7.80	Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. ( Chachin, M; Daida, H; Hirayama, A; Ishiguro, N; Kawai, S; Sugioka, T; Tanahashi, N, 2014)
"Celecoxib for the treatment of pain resulting from osteoarthritis (OA) was reviewed by the Tandvårds- och läkemedelsförmånsverket-Dental and Pharmaceutical Benefits Board (TLV) in Sweden in late 2010."	7.80	A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. ( Akehurst, R; Brereton, N; Ekelund, M; Pennington, B, 2014)
"The National Institute for Health and Clinical Excellence (NICE) health economic model for assessing the cost-effectiveness of celecoxib plus a proton pump inhibitor (PPI) compared to diclofenac plus PPI in the treatment of osteoarthritis has been updated using new adverse event (AE) risks from the CONDOR trial."	7.78	The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial. ( Akehurst, R; Brereton, N; Winn, B, 2012)
" This study was carried out to investigate the effect of SMN, Celecoxib (CLX) individually and in combination on monoiodoacetate (MIA)-induced osteoarthritis (OA) in rat."	7.78	Silymarin potentiates the anti-inflammatory effects of Celecoxib on chemically induced osteoarthritis in rats. ( Amniattalab, A; Ashkavand, Z; Malekinejad, H; Rezaei-Golmisheh, A; Vishwanath, BS, 2012)
" Recently, head-to-head, randomized, controlled trials have shown a significantly higher incidence of blood pressure (BP) destabilization and clinically significant edema with rofecoxib than with celecoxib among older, hypertensive patients with osteoarthritis (OA)."	7.72	A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003)
"To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care."	7.72	Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004)
"To report a case of acute methemoglobinemia in a patient treated with celecoxib for osteoarthritis."	7.72	Celecoxib-induced methemoglobinemia. ( Banda, VR; Campo, NJ; Hayes, SD; Kaushik, P; Kaushik, R; Zuckerman, SJ, 2004)
" We describe a 67-year-old man taking a higher than usual dose of celecoxib (Celebrex) for osteoarthritis with resultant gastric erosions, ulceration, and a significant gastrointestinal (GI) hemorrhage."	7.71	Celecoxib-induced upper gastrointestinal hemorrhage and ulceration. ( Crawford, AS; White, JG, 2002)
"The Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic model was used to evaluate the economic and health impact of the recent introduction of celecoxib for treatment of osteoarthritis (OA) and rheumatoid arthritis (RA) in Sweden."	7.70	The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Haglund, U; Svarvar, P, 2000)
" The hypothesis is that compared to placebo with opioids as rescue treatment, sequential use of parecoxib and celecoxib can achieve less morphine consumption over the postoperative 2 weeks, as well as better pain control, quicker functional recovery in the postoperative 6 weeks and less opioid-related adverse events during the 12-week recovery phase."	6.82	Efficacy and safety of Postoperative Intravenous Parecoxib sodium Followed by ORal CElecoxib (PIPFORCE) post-total knee arthroplasty in patients with osteoarthritis: a study protocol for a multicentre, double-blind, parallel-group trial. ( Bian, Y; Feng, B; Jiang, J; Lin, J; Pei, F; Shen, B; Sun, T; Wang, W; Weng, X; Yan, S; Zhang, M; Zhuang, Q, 2016)
"Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study."	6.72	Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006)
"Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1."	6.69	Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)
"Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases."	6.58	Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. ( Angeli, F; Reboldi, G; Signorotti, S; Trapasso, M; Verdecchia, P, 2018)
" There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo."	6.53	Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016)
"Celecoxib was shown to affect all structures involved in OA pathogenesis: cartilage, bone, and synovium."	6.47	Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. ( Bijlsma, JW; de Boer, TN; Lafeber, FP; Mastbergen, SC; van Roon, J; Zweers, MC, 2011)
"Celecoxib would appear to be a useful option for therapy in patients at high risk for NSAID-induced GI toxicity, or in those responding suboptimally to or intolerant of NSAIDs."	6.47	Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. ( McCormack, PL, 2011)
"Celecoxib has shown significant equivalent anti-inflammatory and analgesic efficacy and has produced less endoscopically apparent gastrointestinal (GI) ulceration or erosion than have 3 classic NSAIDs."	6.40	Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. ( Goldenberg, MM, 1999)
"Metformin was administered orally every day to rats with OA."	5.62	Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021)
"Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs)."	5.48	Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10. ( Cho, KH; Cho, ML; Choi, J; Jung, K; Kim, SJ; Kwon, JY; Lee, CY; Lee, SH; Na, HS; Park, SH; Shin, DY, 2018)
" In the present study, we aimed to evaluate the treatment effect of celecoxib (CLX) combined with diacerein (DC) on OA and delineate the underlying molecular mechanism."	5.42	Celecoxib Combined with Diacerein Effectively Alleviates Osteoarthritis in Rats via Regulating JNK and p38MAPK Signaling Pathways. ( Li, G; Li, Y; Li, Z; Meng, D; Tian, K; Xu, J, 2015)
"An observational study of GERD patients with a diagnosis of OA/RA using two separate databases, the IMS Lifelink Health Plan Claims Database (PharMetrics) and Market Scan Claims Database (Medstat) was conducted."	5.37	Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis. ( Assaf, AR; Cryer, B; Luo, X; Mardekian, J; Sands, G, 2011)
"NAXOZOL was not inferior to celecoxib in protecting the gastrointestinal tract and providing pain relief in patients with osteoarthritis."	5.34	A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis. ( Kang, CN; Kim, HJ; Kim, JH; Lee, S; Lee, WS; Moon, SH; Park, MS; Shin, SJ, 2020)
"Samples were from a randomized, parallel, double-blind trial of pharmaceutical grade 1500 mg GH + 1200 mg CS (n=96) versus 200 mg celecoxib daily (n=93) for 6- months in knee osteoarthritis (OA) patients."	5.34	Differences in Serum Biomarkers Between Combined Glucosamine and Chondroitin Versus Celecoxib in a Randomized, Double-blind Trial in Osteoarthritis Patients. ( Herrero, M; Ladd, J; Lampe, JW; Lampe, PD; Lo, E; Martinez, H; Navarro, SL; Randolph, TW; Shelley, D; Zhang, Y, 2020)
"Both membranous glomerulopathy and acute interstitial nephritis have been reported to occur following treatment with non-steroidal anti-inflammatory drugs."	5.32	Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. ( Appel, GB; D'Agati, VD; Falkowitz, DC; Imaizumi, S; Isom, R; Markowitz, GS; Zaki, M, 2003)
"Celecoxib was dominated by diclofenac in average-risk patients."	5.32	The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003)
"To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA)."	5.27	Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. ( Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018)
" Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b."	5.27	Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. ( Bao, W; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Nissen, SE; Solomon, DH; Stevens, T; Vargo, J; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018)
"In this double-blind, randomized, multicentre non-inferiority CV-safety trial, 444 patients (mean age 62 ± 10 years, 54% female) with osteoarthritis (92%) or rheumatoid arthritis (8%) and evidence of or at increased risk for coronary artery disease received celecoxib (100-200 mg bid), ibuprofen (600-800 mg tid), or naproxen (375-500 mg bid) with matching placebos in a 1: 1: 1 allocation, to assess the effect on 24-h ambulatory BP after 4 months."	5.24	Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) ( Beckerman, B; Borer, JS; Davey, DA; Fayyad, R; Flammer, AJ; Graham, DY; Husni, ME; Iorga, D; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wisniewski, LM; Yeomans, ND, 2017)
"Patients aged 60 years and over with osteoarthritis or rheumatoid arthritis, free from established CV disease and taking chronic prescribed nsNSAIDs, were randomized to switch to celecoxib or to continue their previous nsNSAID."	5.24	Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). ( Connolly, E; Findlay, E; Ford, I; Greenlaw, N; Grobbee, DE; Hallas, J; Hawkey, CJ; Hobbs, FDR; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Perez-Gutthann, S; Ralston, SH; Reid, DM; Ritchie, LD; Ruschitzka, F; Scheiman, JM; Walters, MR; Webster, J; Wei, L; Wilson, A, 2017)
"To describe utilization patterns of duloxetine and celecoxib and subsequent opioid use among patients with osteoarthritis."	5.17	Utilization of duloxetine and celecoxib in osteoarthritis patients. ( Andrews, JS; Chen, SY; Novick, D; Peng, X; Wu, N; Yu, X, 2013)
" Omeprazole and Diclofenac for At-Risk Osteoarthritis and Rheumatoid Arthritis Patients (CONDOR) trial showed that a haemoglobin drop ≥2 g/dL adjudicated as either of defined or presumed GI origin was the most frequent component/event for the composite GI primary end point."	5.16	Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). ( Chan, FK; Goldstein, JL; Lanas, A; Li, C; Peura, DA; Sands, GH; Scheiman, JM; Wilcox, CM, 2012)
"We measured the urinary excretion of ATL in 24 patients with both ischaemic heart disease and osteoarthritis, chronically treated with aspirin and co-administered celecoxib 200 mg b."	5.14	Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. ( De Caterina, R; Renda, G; Romano, M; Zurro, M, 2010)
"To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors."	5.14	Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010)
"The SF-36 Quality of Life questionnaire was used in this prospective multicenter study to evaluate changes in pain intensity and quality of life in 2339 patients with osteoarthritis treated by 1244 general practitioners with celecoxib (200 mg per day) for 4 weeks."	5.13	[Changes in quality of life in patients with osteoarthritis treated with celecoxib: the Qualice study]. ( Jeanpetit, Y; Méric, G; Rozenberg, S, 2008)
"Randomized clinical trials evaluating ultramicronised diclofenac, diclofenac, celecoxib, etodolac and placebo in patients with osteoarthritis were identified."	5.12	Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis. ( Auletta, LL; de Almeida Macedo, E; de Campos, GC; Kummer, AM; Millan Fachi, M; Papaleo Rosim, M, 2021)
"We included randomized controlled trials of oral celecoxib compared with a non-selective NSAID or placebo in rheumatoid arthritis and osteoarthritis patients."	5.12	Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis. ( Chen, JQ; Cheng, BR; Gao, QY; Li, WH; Liu, JP; Wu, CJ; Xing, JL; Yan, LJ; Zhang, XW; Zhang, YQ, 2021)
"To compare the lower osteoarthritis (OA) dose of rofecoxib to the recommended dose of celecoxib in two identically designed studies."	5.12	Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. ( Birbara, C; Chang, DJ; Petruschke, RA; Rodgers, A; Ruoff, G; Sheldon, E; Tershakovec, AM; Valenzuela, C, 2006)
"To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis."	5.12	Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. ( Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C, 2006)
" As an application, we compared gastrointestinal tolerability in persons treated with diclofenac and celecoxib for osteoarthritis."	5.12	A randomized database study in general practice yielded quality data but patient recruitment in routine consultation was not practical. ( Dieleman, JP; Mosis, G; Stricker, BCh; Sturkenboom, MC; van der Lei, J, 2006)
"To assess the use of n-of-1 trials for short-term choice of drugs for osteoarthritis, with particular reference to comparing the efficacy of sustained-release [SR] paracetamol with celecoxib in individual patients."	5.12	Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. ( Brown, RM; Del Mar, CB; McNairn, N; Nikles, CJ; Schluter, PJ; Yelland, MJ, 2007)
"To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare."	5.12	A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. ( De Clerck, L; De Keyser, F; Geusens, P; Hauzeur, JP; Luyten, FP; Malaise, M; Mathy, L; Raeman, F; Van den Bosch, F; Vander Mijnsbrugge, D; Westhovens, R, 2007)
"To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies."	5.12	Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. ( Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM, 2007)
"The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in osteoarthritis (OA) and rheumatoid arthritis (RA) patients."	5.12	Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. ( Lefkowith, JL; Verburg, KM; West, CR; Whelton, A, 2006)
"We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease."	5.12	Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006)
"Subjects 18 years or older with osteoarthritis, without gastroduodenal ulcer or erosive esophagitis at baseline endoscopy, and a cardiovascular indication for prophylaxis low-dose (81 or 325 mg) aspirin were prescribed open-label aspirin and blindly randomized to celecoxib 200 mg/day or naproxen 500 mg twice daily plus lansoprazole 30 mg once daily."	5.12	Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. ( Amer, F; Cryer, B; Goldstein, JL; Hunt, B, 2007)
"5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) as add-on therapy for subjects with osteoarthritis (OA) pain inadequately controlled by COX-2 nonsteroidal antiinflammatory drugs (NSAID)."	5.11	Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. ( Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC, 2004)
"In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd."	5.11	Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004)
" In well designed clinical trials of 1-52 weeks' duration in patients with osteoarthritis (OA) or rheumatoid arthritis, the efficacy of oral lumiracoxib 100-400 mg/day in decreasing pain intensity and improving functional status was greater than that with placebo and similar to those with nonselective NSAIDs or celecoxib 200mg once daily."	5.11	Lumiracoxib. ( Curran, MP; Lyseng-Williamson, KA, 2004)
"To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)."	5.11	Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005)
" Therefore, we conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis."	5.11	The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. ( Brabant, T; Fort, JG; Kivitz, A; Pitt, B; Simon, LS; Sowers, JR; van Ingen, H; Whelton, A; White, WB; Winer, N, 2005)
" This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens."	5.10	Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002)
"An open-label multicentre study was conducted in primary care centres in Spain to investigate the effect of a switch from celecoxib to rofecoxib among patients with osteoarthritis and to identify factors associated with a good response to rofecoxib treatment."	5.10	Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. ( Collantes-Estevez, E; Fernandez-Perez, C, 2003)
"The present data confirm our previous observations in patients with rheumatoid arthritis, further suggesting that nimesulide represents an effective agent for the treatment of joint pain, with particular reference to the rapid onset of its analgesic effect."	5.10	A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. ( Bianchi, M; Broggini, M, 2003)
"To compare the efficacy of the cyclooxygenase 2 (COX-2)-specific inhibitors celecoxib and rofecoxib in treating the signs and symptoms of osteoarthritis (OA)."	5.10	Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. ( Fort, JG; Gibofsky, A; McKenna, F; Williams, GW, 2003)
"To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability."	5.10	Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002)
"To evaluate the functional status of patients with signs and symptoms of osteoarthritis of the knee after treatment with celecoxib compared with placebo and naproxen."	5.09	Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. ( Dedhiya, SD; Markenson, JA; McMillen, JI; Osterhaus, JT; Yu, SS; Zhao, SZ; Zhao, WW, 1999)
"To compare the efficacy and safety of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, with those of naproxen, a nonsteroidal anti-inflammatory drug (NSAID), and placebo in the treatment of osteoarthritis of the knee."	5.09	Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. ( Bensen, WG; Fiechtner, JJ; Geis, GS; Hubbard, RC; Isakson, PC; McMillen, JI; Verburg, KM; Woods, EM; Yu, SS; Zhao, WW, 1999)
"To determine the upper gastrointestinal (GI) tolerability of celecoxib, naproxen, and placebo in patients with rheumatoid arthritis (RA) and osteoarthritis (OA)."	5.09	Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. ( Agrawal, NM; Bensen, WG; Burke, TA; Geis, GS; Makuch, RW; Maurath, CJ; Zabinski, RA; Zhao, SZ, 2000)
"This study evaluates the impact of celecoxib on functional status, health-related quality of life (HRQOL), and safety of elderly patients (> or =70 years) with osteoarthritis (OA) of the knee and/or hip."	5.09	Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. ( Dedhiya, SD; Espinoza, L; Lisse, J; Osterhaus, JT; Zhao, SZ, 2001)
" In the upper GI endoscopy study, 19% of subjects receiving naproxen (6 of 32) developed gastric ulcers, whereas no ulcers occurred in subjects receiving SC-58635 or placebo."	5.08	Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. ( Geis, GS; Hubbard, RC; Isakson, PC; Lanza, FL; Lipsky, PE; Schwartz, BD; Simon, LS; Talwalker, S, 1998)
"The US Food and Drug Administration recently granted an approved indication for the first fixed-dose combination antihypertensive (amlodipine) and nonsteroidal anti-inflammatory drug (celecoxib) for treatment of comorbid hypertension and osteoarthritis."	5.01	Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. ( Cooper-DeHoff, RM; Smith, SM, 2019)
"This study aimed to assess the relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen at recommended dosages in patients with osteoarthritis (OA)."	4.93	Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. ( Choi, SJ; Ji, JD; Kim, JH; Lee, YH; Seo, YH; Song, GG, 2016)
"The efficacy of celecoxib as an analgesic was comparable to that of loxoprofen, whereas serious GI events, including symptomatic ulcers, were significantly less frequent with celecoxib than with loxoprofen in Japanese patients with rheumatoid arthritis (RA) and osteoarthritis (OA) (p = 0."	4.87	Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. ( Sakamoto, C; Soen, S, 2011)
"The objective was to improve understanding of adverse events occurring with celecoxib in the treatment of osteoarthritis and rheumatoid arthritis."	4.82	Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. ( Derry, S; Makinson, GT; McQuay, HJ; Moore, RA, 2005)
"To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 (COX 2) inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis."	4.81	Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. ( Bradley, MD; Deeks, JJ; Smith, LA, 2002)
" Celecoxib, an anti-inflammatory and analgesic agent indicated for the treatment of osteoarthritis and rheumatoid arthritis, is the first cyclooxygenase (COX) inhibitor with well-defined cyclooxygenase-2 (COX-2) specificity."	4.80	Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. ( Tindall, E, 1999)
"Celecoxib is the first COX-2 specific inhibitor approved for use in osteoarthritis and rheumatoid arthritis."	4.80	Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. ( Clemett, D; Goa, KL, 2000)
"Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis."	4.80	Celecoxib clinical profile. ( Tive, L, 2000)
"Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis."	4.80	The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. ( Geis, GS; Maddrey, WC; Maurath, CJ; Verburg, KM, 2000)
"The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis."	4.80	Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. ( Geis, GS; Maurath, CJ; Verburg, KM; Whelton, A, 2000)
" Destabilization of the medial meniscus (DMM) using a mouse model was combined with three approaches: the treatment of celecoxib, capsaicin, and sensory nerve-specific prostaglandin E2 receptor 4 (EP4)-knockout mice."	4.12	Inhibition of PGE2 in Subchondral Bone Attenuates Osteoarthritis. ( Cai, M; Ding, Y; Li, H; Li, S; Li, Y; Sun, Q; Xie, W; Zhang, Y, 2022)
"This paper aims at demonstrating silk fibroin nanoparticles (SFNs) promote anti-inflammatory properties of celecoxib (CXB) or curcumin (CUR), and could be exploited for osteoarthritis (OA) treatment."	3.91	Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis. ( Bari, E; Catenacci, L; Crivelli, B; Faragò, S; Mocchi, M; Perteghella, S; Prina-Mello, A; Sorrenti, M; Torre, ML; Tripodo, G, 2019)
"Targeted and untargeted metabolomics were used to investigate the effect of COX-2 deletion or inhibition in mice and in osteoarthritis patients exposed to nonsteroidal anti-inflammatory drugs on the l-arginine/nitric oxide pathway."	3.88	Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs. ( Briggs, WTE; Castro, C; FitzGerald, GA; Griffin, JL; Karlson, EW; Lahens, NF; Li, X; Malik, D; Meng, H; Rhoades, SD; Ricciotti, E; Sparks, JA; Tang, SY; Weljie, AM; West, JA, 2018)
"We used the National Health Insurance Service-National Sample Cohort (NHIS-NSC) to investigate patients over 20 years old with osteoarthritis and rheumatoid arthritis who received a single prescription of SKI306X, celecoxib or naproxen at least once from January 1, 2011 through December 31, 2012."	3.85	Evaluation of cardiovascular risk associated with SKI306X use in patients with osteoarthritis and rheumatoid arthritis. ( Hyun, MK; Woo, Y, 2017)
"In this study, we investigated the potential of celecoxib-loaded polyester amide (PEA) microspheres as an auto-regulating drug delivery system for the treatment of pain associated with knee osteoarthritis (OA)."	3.83	Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection. ( Draaisma, G; Emans, PJ; Gijbels, M; Janssen, M; Mihov, G; Thies, J; Timur, UT; van Rhijn, LW; Welting, TJ; Woike, N, 2016)
"Results of the CONDOR study suggest that in osteoarthritis and rheumatoid arthritis patients at elevated risk of gastrointestinal (GI) events, treatment with celecoxib, a cyclooxygenase (COX)-2 selective non-steroidal anti-inflammatory drug (NSAID), demonstrated significantly lower toxicity in the upper and lower (GI) tract when compared to the non-selective NSAID diclofenac plus a proton-pump-inhibitor (PPI), omeprazole."	3.81	How to mechanistically explain the CONDOR study data. ( Buttgereit, F; Spies, CM; Stemmler, E, 2015)
"A prospective, 3-year comparative observational study compared the risk of cardiovascular events in patients with osteoarthritis or rheumatoid arthritis prescribed celecoxib or a nonsteroidal antiinflammatory drug (NSAID)."	3.80	Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. ( Chachin, M; Daida, H; Hirayama, A; Ishiguro, N; Kawai, S; Sugioka, T; Tanahashi, N, 2014)
" Celecoxib Outcome Trial (SCOT), a clinical trial investigating the cardiovascular safety of non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis."	3.80	Effectiveness of newspaper advertising for patient recruitment into a clinical trial. ( Hapca, A; Jennings, CG; MacDonald, TM; Mackenzie, IS; Wei, L; Wilson, A, 2014)
"Celecoxib for the treatment of pain resulting from osteoarthritis (OA) was reviewed by the Tandvårds- och läkemedelsförmånsverket-Dental and Pharmaceutical Benefits Board (TLV) in Sweden in late 2010."	3.80	A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. ( Akehurst, R; Brereton, N; Ekelund, M; Pennington, B, 2014)
" Western blot analysis identified 21 kDa lipocalin (L)-prostaglandin D2 (PGD2) synthase (S) in human osteoarthritis (OA)-affected cartilage, whose expression was increased by IL-1β and TNFα."	3.79	Yin-Yang regulation of prostaglandins and nitric oxide by PGD2 in human arthritis: reversal by celecoxib. ( Amin, AR; Dave, M, 2013)
"The effects of long-term use of celecoxib, ibuprofen, and indomethacin on types I, II, and III collagen metabolism were evaluated in rat osteoarthritis (OA) model."	3.78	The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model. ( An, H; Jiang, DM; Luo, XJ; Ou, YS; Quan, ZX; Tan, C; Tang, K, 2012)
"The National Institute for Health and Clinical Excellence (NICE) health economic model for assessing the cost-effectiveness of celecoxib plus a proton pump inhibitor (PPI) compared to diclofenac plus PPI in the treatment of osteoarthritis has been updated using new adverse event (AE) risks from the CONDOR trial."	3.78	The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial. ( Akehurst, R; Brereton, N; Winn, B, 2012)
" This study was carried out to investigate the effect of SMN, Celecoxib (CLX) individually and in combination on monoiodoacetate (MIA)-induced osteoarthritis (OA) in rat."	3.78	Silymarin potentiates the anti-inflammatory effects of Celecoxib on chemically induced osteoarthritis in rats. ( Amniattalab, A; Ashkavand, Z; Malekinejad, H; Rezaei-Golmisheh, A; Vishwanath, BS, 2012)
"The purpose of this study was to compare the gait parameters recorded on the CatWalk and the mechanical sensitivity with von Frey filaments of two putative models of osteoarthritis over a one month period, and to evaluate the effect of celecoxib on these parameters."	3.77	Gait analysis and pain response of two rodent models of osteoarthritis. ( Beaudry, F; Ferland, CE; Laverty, S; Vachon, P, 2011)
"Explants from human osteoarthritis cartilage were cultured alone or in IL-1α for 7 days with or without Phellodendron amurense ethanol extract or celecoxib (40, 100, 200μg/ml)."	3.77	Effect of Phellodendron amurense in protecting human osteoarthritic cartilage and chondrocytes. ( Baek, YH; Choi, DY; Huh, JE; Kim, JH; Lee, JD; Park, DS, 2011)
"To compare the incidence of serious gastrointestinal (GI) complications and associated medical costs in a population with either osteoarthritis (OA) or rheumatoid arthritis (RA) enrolled in Medicare plans with celecoxib formulary restrictions versus plans without such restrictions."	3.77	Impact of Celecoxib restrictions in medicare beneficiaries with arthritis. ( Ball, AT; Cappelleri, JC; Deminski, MC; Joshi, AV; Louder, AM; Sanchez, RJ, 2011)
") were assessed using acetic acid-induced vascular permeability, carrageenan-induced paw edema, and croton oil-induced ear edema."	3.76	The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo. ( Cho, YB; Hur, J; Jung, I; Jung, KC; Kang, JY; Kang, M; Kim, KS; Kim, SH; Lee, JD; Lee, JH; Park, DS; Yoo, MC, 2010)
"The study of the E2 and F2alpha (prostaglandins levels in the blood and mucous coat of the stomach was conducted in 20 patients with stomach ulcer, 15 patients with osteoarthritis taking diclofenac and 16 patients taking celecoxib."	3.73	[Role of prostaglandins in the pathogenesis of stomach ulcer and gastropathy caused by non-steroid anti-inflammatory drugs]. ( Kolomiets, EV; Lazebnik, LB; Tkachenko, VN, 2005)
" This study evaluated average daily doses and costs of rofecoxib and celecoxib and concomitant use of gastroprotective agents (GPAs) in elderly patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in Quebec, prior to the rofecoxib withdrawal."	3.73	Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? ( Chabot, I; Hunsche, E; Rahme, E; Toubouti, Y, 2006)
" Recently, head-to-head, randomized, controlled trials have shown a significantly higher incidence of blood pressure (BP) destabilization and clinically significant edema with rofecoxib than with celecoxib among older, hypertensive patients with osteoarthritis (OA)."	3.72	A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003)
"To assess the effects of celecoxib, a cyclooxygenase (COX-2) selective inhibitor, on the metabolism of hyaluronan (HA) and proteoglycans (PG) in human cartilage explants with midrange severity of osteoarthritis (OA)."	3.72	Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. ( Devogelaer, JP; El Hajjaji, H; Manicourt, DH; Marcelis, A, 2003)
"This study assessed prescribing patterns for rofecoxib and celecoxib in the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as differences in prescribing patterns across physician specialties."	3.72	An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. ( Kong, SX; Mavros, P; Mitchell, JH; Pellissier, JM; Schnitzer, TJ; Straus, WL; Watson, DJ, 2003)
"A total of 3639 patients with rheumatoid arthritis (RA), osteoarthritis, and fibromyalgia starting therapy of celecoxib, rofecoxib, naproxen, or ibuprofen were surveyed at 6-month intervals for up to 2."	3.72	Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. ( Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ, 2004)
"To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care."	3.72	Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004)
"To report a case of acute methemoglobinemia in a patient treated with celecoxib for osteoarthritis."	3.72	Celecoxib-induced methemoglobinemia. ( Banda, VR; Campo, NJ; Hayes, SD; Kaushik, P; Kaushik, R; Zuckerman, SJ, 2004)
"The aim of this study was to describe physician-reported management of clinically significant edema and/or destabilized blood pressure in patients with osteoarthritis (OA) and hypertension when initiating therapy with rofecoxib or celecoxib."	3.71	Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. ( Bristol, S; Burke, TA; May, C; Osterhaus, JT; Wentworth, C; Whelton, A, 2002)
"To analyse the cost of celecoxib (selective cyclo-oxygenase-2 inhibitor) and conventional NSAID regimens for the treatment of osteoarthritis and rheumatoid arthritis from the perspective of a public health organization in Hong Kong."	3.71	Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. ( Chan, FK; Chan, TY; Lau, WH; Lee, KK; You, JH, 2002)
" We describe a 67-year-old man taking a higher than usual dose of celecoxib (Celebrex) for osteoarthritis with resultant gastric erosions, ulceration, and a significant gastrointestinal (GI) hemorrhage."	3.71	Celecoxib-induced upper gastrointestinal hemorrhage and ulceration. ( Crawford, AS; White, JG, 2002)
"A population of 6637 patients with rheumatoid arthritis (RA) and osteoarthritis (OA) from the practices of 433 US rheumatologists completed 2 sets of detailed questionnaires concerning (1) the last 6 months in 1998 and (2) the first 6 months of 1999, generally prior to and after the release of celecoxib and rofecoxib."	3.71	Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr ( Arguelles, LM; Burke, TA; Flowers, N; Pettitt, D; Wolfe, F, 2002)
"The Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic model was used to evaluate the economic and health impact of the recent introduction of celecoxib for treatment of osteoarthritis (OA) and rheumatoid arthritis (RA) in Sweden."	3.70	The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Haglund, U; Svarvar, P, 2000)
" This work led to the identification of 1i (4-[5-(4-methylphenyl)-3-(trifluoromethyl)- H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis."	3.69	Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). ( Bertenshaw, SR; Burton, EG; Carter, JS; Cogburn, JN; Collins, PW; Docter, S; Graneto, MJ; Gregory, SA; Isakson, PC; Koboldt, CM; Lee, LF; Malecha, JW; Miyashiro, JM; Penning, TD; Perkins, WE; Rogers, RS; Rogier, DJ; Seibert, K; Talley, JJ; Veenhuizen, AW; Yu, SS; Zhang, YY, 1997)
" The risk score was designed to predict the 1-year occurrence of major toxicity among NSAID users, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality."	2.90	Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. ( Husni, ME; Nissen, S; Paynter, N; Shao, M; Solomon, DH; Wolski, K, 2019)
" The outcome was major nonsteroidal anti-inflammatory drug toxicity, including time to first occurrence of major adverse cardiovascular events, important gastrointestinal events, renal events, and all-cause mortality."	2.84	The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. ( Borer, JS; Brennan, DM; Husni, ME; Libby, PA; Lincoff, AM; Lϋscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wisniewski, LM; Yeomans, ND, 2017)
"Unfavourable effects, or risks, included opioid dependence, nonfatal myocardial infarction and rapidly progressive OA leading to total joint replacement."	2.82	Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis. ( Bullok, K; Hauber, B; Junor, R; Markman, J; Mauer, J; Russo, L; Tervonen, T; Watt, S; Whalen, E, 2022)
" The hypothesis is that compared to placebo with opioids as rescue treatment, sequential use of parecoxib and celecoxib can achieve less morphine consumption over the postoperative 2 weeks, as well as better pain control, quicker functional recovery in the postoperative 6 weeks and less opioid-related adverse events during the 12-week recovery phase."	2.82	Efficacy and safety of Postoperative Intravenous Parecoxib sodium Followed by ORal CElecoxib (PIPFORCE) post-total knee arthroplasty in patients with osteoarthritis: a study protocol for a multicentre, double-blind, parallel-group trial. ( Bian, Y; Feng, B; Jiang, J; Lin, J; Pei, F; Shen, B; Sun, T; Wang, W; Weng, X; Yan, S; Zhang, M; Zhuang, Q, 2016)
" Future clinical trials should investigate this association with maximum dosage of drugs, increased treatment duration, and monitoring of social and environmental changes."	2.78	NSAIDs are associated with lower depression scores in patients with osteoarthritis. ( Aneja, A; Farkouh, ME; Gandhi, S; Greenberg, J; Iyengar, RL; Mosovich, S; Razzouk, L; Thorpe, K, 2013)
"Celecoxib was associated with a lower risk of clinically significant upper and/or lower GI events than nsNSAIDs."	2.78	GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. ( Berger, MF; Cryer, B; Li, C; Simon, LS; Singh, G; Stillman, MJ, 2013)
"Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study."	2.72	Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006)
"Rofecoxib caused an increase in BP compared to celecoxib; a change in recumbent systolic BP +/- SD (6."	2.72	Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? ( Aw, TJ; Billah, B; Krum, H; Liew, D; Morel-Kopp, MC; Schneider, HG; Tofler, GH, 2006)
" Differences observed in blood pressure response between COX inhibitors may not be related in their sensitivity but rather their dosing frequency."	2.71	Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. ( Alausa, T; Bakris, GL; Folker, A; Hung, E; Izhar, M, 2004)
"The treatment of 20 osteoarthrosis patients was carried out with the help of Celecoxib while 18 patients were on Tramadol as an analgesic therapy against a standard antiulcer therapy."	2.71	[Celecoxib and Tramadol as an alternative osteoarthrosis therapy in patients with NSAID gastropathy]. ( Drozdov, VN; Kolomiets, EV; Lazebnik, LB; Li, IA, 2004)
"Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1."	2.69	Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)
"Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases."	2.58	Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. ( Angeli, F; Reboldi, G; Signorotti, S; Trapasso, M; Verdecchia, P, 2018)
"The polysaccharides used in the treatment of osteoarthritis (OA) mainly include sodium hyaluronate, chondroitin sulfate, chitosan, xanthan gum, Low molecular weight heparin, alginate and other polysaccharides."	2.55	Recent advances in polysaccharides for osteoarthritis therapy. ( Chen, Q; Han, G; Ling, P; Liu, F; Shao, X; Wang, F, 2017)
" There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo."	2.53	Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016)
" For older adult patients at higher risk for NSAID-related adverse effects, such as those who have gastrointestinal or cardiovascular disease, diabetes mellitus, or who are taking low-dose aspirin, opioids are recommended instead."	2.49	Opioids for chronic pain: new evidence, new strategies, safe prescribing. ( de Leon-Casasola, OA, 2013)
"Osteoarthritis and rheumatoid arthritis are conditions that are associated with significant clinical burden, and impact on patients' functional status and quality of life."	2.48	Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. ( Foster, TS; Huelin, R; Mould, JF; Pokora, T, 2012)
"Celecoxib was shown to affect all structures involved in OA pathogenesis: cartilage, bone, and synovium."	2.47	Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. ( Bijlsma, JW; de Boer, TN; Lafeber, FP; Mastbergen, SC; van Roon, J; Zweers, MC, 2011)
"Celecoxib would appear to be a useful option for therapy in patients at high risk for NSAID-induced GI toxicity, or in those responding suboptimally to or intolerant of NSAIDs."	2.47	Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. ( McCormack, PL, 2011)
" Following oral administration, the less lipophilic celecoxib has a lower bioavailability (20-40%) than the other two coxibs (74-100%)."	2.44	Clinical use and pharmacological properties of selective COX-2 inhibitors. ( Klotz, U; Shi, S, 2008)
" However, recent studies showed that long term use of high doses of celecoxib is associated with an increased cardiovascular toxicity."	2.44	Compositions for treatment of cancer and inflammation. ( Arber, N; Lev-Ari, S; Lichtenberg, D, 2008)
" However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications."	2.41	Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000)
" The usual recommended daily dosage of celecoxib is 200 mg (in one or two intakes per day), to be increased up to 400 mg (two intakes per day) if necessary."	2.41	[Pharma-clinics. The drug of the month. Celecoxib (Celebrex)]. ( Scheen, AJ, 2001)
" During repeated dosage with the specific COX-2 inhibitors, the 24 hour urinary excretion of sodium is only inhibited for the first day of treatment while the excretion of sodium is still decreased over the first 3 hours after the individual doses."	2.41	Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). ( Day, RO; Graham, GG; Graham, RI, 2002)
"Celecoxib and rofecoxib have been used in Norway since 2000."	2.41	[A critical evaluation of side effect data on COX-2 inhibitors]. ( Pomp, E, 2002)
"Pain is the major symptom that leads patients to consult their physicians for the treatment of arthritis; therefore, effective pain control is an important goal in the management of this disorder."	2.40	Pain management in osteoarthritis: the role of COX-2 inhibitors. ( Lane, NE, 1997)
"Celecoxib has shown significant equivalent anti-inflammatory and analgesic efficacy and has produced less endoscopically apparent gastrointestinal (GI) ulceration or erosion than have 3 classic NSAIDs."	2.40	Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. ( Goldenberg, MM, 1999)
"Metformin was administered orally every day to rats with OA."	1.62	Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021)
"Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs)."	1.48	Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10. ( Cho, KH; Cho, ML; Choi, J; Jung, K; Kim, SJ; Kwon, JY; Lee, CY; Lee, SH; Na, HS; Park, SH; Shin, DY, 2018)
" In the present study, we aimed to evaluate the treatment effect of celecoxib (CLX) combined with diacerein (DC) on OA and delineate the underlying molecular mechanism."	1.42	Celecoxib Combined with Diacerein Effectively Alleviates Osteoarthritis in Rats via Regulating JNK and p38MAPK Signaling Pathways. ( Li, G; Li, Y; Li, Z; Meng, D; Tian, K; Xu, J, 2015)
"Celecoxib was chosen as a comparator, given its clinical efficacy for alleviating pain in osteoarthritis patients and its peripheral and central pharmacological action."	1.39	Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. ( Baker, SJ; Bannon, A; Beaver, J; Cassar, S; Chandran, P; Day, M; Fox, GB; Hart, M; Honore, P; Hooker, BA; Joshi, SK; Kamath, RV; Medema, JK; Mikusa, JP; Rajagovindan, R; Tovcimak, A; Upadhyay, J; Wald, MJ, 2013)
"Celecoxib has a positive effect on human osteoarthritic cartilage, but the mechanisms remain unclear."	1.38	Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte. ( An, H; Jiang, D; Luo, X; Ou, Y; Quan, Z; Tan, C; Tang, K, 2012)
"An observational study of GERD patients with a diagnosis of OA/RA using two separate databases, the IMS Lifelink Health Plan Claims Database (PharMetrics) and Market Scan Claims Database (Medstat) was conducted."	1.37	Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis. ( Assaf, AR; Cryer, B; Luo, X; Mardekian, J; Sands, G, 2011)
"Celecoxib and naproxen were not associated with increased risks."	1.35	Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. ( Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J, 2008)
"Osteoarthritis is a chronic and progressive joint disease."	1.34	[Articular cartilage in osteoarthritic patients: effects of diclofenac, celecoxib and glucosamine sulfate on inflammatory markers]. ( Brizuela, NY; Demurtas, SL; Meirovich, CI; Montrull, HL, 2007)
"Eosinophilic fasciitis (EF) is a rare connective tissue disorder characterized by symmetrical sclerodermatous skin changes primarily affecting the extremities and histologically, by thickening of the fascia with chronic inflammatory infiltrate containing eosinophils."	1.34	Eosinophilic fasciitis in a 57-year-old Japanese-American woman. ( Ambrocio, DU; Uramoto, K, 2007)
"Among 7."	1.33	Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? ( Coupal, L; Grover, SA; Zowall, H, 2005)
"Celecoxib at 1 microM was able to increase synthesis of degenerated cartilage and normalize both releases of newly formed and resident proteoglycans."	1.33	Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. ( Bijlsma, JW; Lafeber, FP; Mastbergen, SC, 2005)
"Both membranous glomerulopathy and acute interstitial nephritis have been reported to occur following treatment with non-steroidal anti-inflammatory drugs."	1.32	Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. ( Appel, GB; D'Agati, VD; Falkowitz, DC; Imaizumi, S; Isom, R; Markowitz, GS; Zaki, M, 2003)
"Celecoxib was dominated by diclofenac in average-risk patients."	1.32	The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003)
"We evaluated their use in the treatment of osteoarthritis by general practitioners, with special attention to concomitant prescription of gastroprotective agents."	1.32	Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. ( Bouée, S; Charlemagne, A; Fagnani, F; Lancry, PJ; Le Jeunne, P; Naudin, F; Sermet, C, 2004)
"Rofecoxib users were at a significantly increased relative risk of new onset hypertension compared with patients taking celecoxib (odds ratio [OR] 1."	1.32	Relationship between COX-2 specific inhibitors and hypertension. ( Avorn, J; Levin, R; Schneeweiss, S; Solomon, DH, 2004)
"Osteoarthritis was the most common indication (68."	1.31	A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. ( Cutts, C; LaCaze, A; Tett, S, 2002)

Research

Studies (243)

Authors

Clinical Trials (22)

Trial Overview

Trial Outcomes

Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	15 (6.17)	18.2507
2000's	138 (56.79)	29.6817
2010's	74 (30.45)	24.3611
2020's	16 (6.58)	2.80

Authors	Studies
Penning, TD	1
Talley, JJ	1
Bertenshaw, SR	1
Carter, JS	1
Collins, PW	1
Docter, S	1
Graneto, MJ	1
Lee, LF	1
Malecha, JW	1
Miyashiro, JM	1
Rogers, RS	1
Rogier, DJ	1
Yu, SS	3
Burton, EG	1
Cogburn, JN	1
Gregory, SA	1
Koboldt, CM	1
Perkins, WE	1
Seibert, K	1
Veenhuizen, AW	1
Zhang, YY	1
Isakson, PC	3
Anzini, M	2
Di Capua, A	1
Valenti, S	1
Brogi, S	1
Rovini, M	1
Giuliani, G	1
Cappelli, A	1
Vomero, S	1
Chiasserini, L	1
Sega, A	1
Poce, G	1
Giorgi, G	1
Calderone, V	1
Martelli, A	1
Testai, L	1
Sautebin, L	1
Rossi, A	1
Pace, S	1
Ghelardini, C	1
Di Cesare Mannelli, L	1
Benetti, V	1
Giordani, A	2
Anzellotti, P	1
Dovizio, M	1
Patrignani, P	2
Biava, M	2
Chen, Q	2
Shao, X	1
Ling, P	1
Liu, F	1
Han, G	1
Wang, F	1
Liu, Q	1
Zhai, L	1
Han, M	1
Shi, D	1
Sun, Z	1
Peng, S	1
Wang, M	1
Zhang, C	1
Gao, J	1
Yan, W	1
Jiang, Q	1
Chen, D	1
Xu, Q	1
Tan, M	1
Sun, Y	1
de Campos, GC	1
de Almeida Macedo, E	1
Kummer, AM	1
Papaleo Rosim, M	1
Millan Fachi, M	1
Auletta, LL	1
Cheng, BR	1
Chen, JQ	1
Zhang, XW	1
Gao, QY	1
Li, WH	1
Yan, LJ	1
Zhang, YQ	1
Wu, CJ	1
Xing, JL	1
Liu, JP	1
Mauer, J	1
Bullok, K	1
Watt, S	1
Whalen, E	1
Russo, L	1
Junor, R	1
Markman, J	1
Hauber, B	1
Tervonen, T	1
Wang, Q	4
Yang, X	2
Gu, X	1
Wei, F	1
Cao, W	1
Zheng, L	1
Li, Y	3
Ma, T	1
Wu, C	1
Kumar, M	1
Dogra, R	1
Mandal, UK	1
Sun, Q	1
Zhang, Y	2
Ding, Y	1
Xie, W	1
Li, H	1
Li, S	1
Cai, M	1
Tellegen, AR	3
Rudnik-Jansen, I	3
Utomo, L	2
Versteeg, S	2
Beukers, M	2
Maarschalkerweerd, R	2
van Zuilen, D	2
van Klaveren, NJ	2
Houben, K	2
Teske, E	2
van Weeren, PR	2
Karssemakers-Degen, N	2
Mihov, G	4
Thies, J	3
Eijkelkamp, N	2
Creemers, LB	3
Meij, BP	3
Tryfonidou, MA	3
Rowan-Robinson, K	1
Park, MS	1
Kang, CN	1
Lee, WS	1
Kim, HJ	2
Lee, S	1
Kim, JH	4
Shin, SJ	1
Moon, SH	1
El-Gogary, RI	1
Khattab, MA	1
Abd-Allah, H	1
Salgado, C	1
Guénée, L	1
Černý, R	1
Allémann, E	1
Jordan, O	1
Zhu, L	1
Yip, KM	1
Tang, Y	1
Liu, Y	1
Jiang, T	1
Zhang, J	1
Zhao, Z	1
Yi, T	1
Chen, H	1
Na, HS	2
Kwon, JY	2
Lee, SY	1
Lee, SH	2
Lee, AR	1
Woo, JS	1
Jung, K	2
Cho, KH	2
Choi, JW	1
Lee, DH	1
Min, HK	1
Park, SH	3
Kim, SJ	2
Cho, ML	3
Piszczatoski, CR	1
Smith, SM	2
Raschle, J	1
Woo, Y	1
Hyun, MK	1
Solomon, DH	6
Husni, ME	5
Libby, PA	1
Yeomans, ND	4
Lincoff, AM	4
Lϋscher, TF	1
Menon, V	3
Brennan, DM	1
Wisniewski, LM	4
Nissen, SE	4
Borer, JS	4
Zolotovskaia, IA	1
Davydkin, IL	1
Breivik, H	1
Jin, Y	1
Smith, C	1
Hu, L	1
Coutant, DE	1
Whitehurst, K	1
Phipps, K	1
McNearney, TA	1
Ackermann, B	1
Pottanat, T	1
Landschulz, W	1
Ruschitzka, F	2
Krum, H	2
Flammer, AJ	1
Libby, P	3
Lüscher, TF	3
Graham, DY	3
Davey, DA	1
Fayyad, R	1
Beckerman, B	1
Iorga, D	1
Jeong, JW	1
Lee, HH	1
Kim, J	1
Choi, EO	1
Hwang-Bo, H	1
Kim, MY	1
Ahn, KI	1
Kim, GY	1
Lee, KW	1
Kim, KY	1
Kim, SG	1
Hong, SH	1
Park, C	1
Cha, HJ	1
Choi, YH	1
Jeong, DH	1
Ullah, HMA	1
Goo, MJ	1
Ghim, SG	1
Hong, IH	1
Kim, AY	1
Jeon, SM	1
Choi, MS	1
Elfadl, AK	1
Chung, MJ	1
Lee, EJ	1
Kim, YD	1
Kim, SY	1
Jeong, KS	1
Wolski, KE	2
Bao, W	2
Berger, MF	4
Stevens, T	1
Vargo, J	1
Walker, C	1
Yang, T	1
Si, H	1
Wu, Y	1
Zeng, Y	1
Pei, F	2
Weng, X	2
Shen, B	2
Pouran, B	1
de Visser, HM	1
Weinans, HH	1
Thomas, RE	1
Kik, MJL	1
Grinwis, GCM	1
Thies, JC	1
Woike, N	2
Emans, PJ	2
Ricciotti, E	1
Castro, C	1
Tang, SY	1
Briggs, WTE	1
West, JA	1
Malik, D	1
Rhoades, SD	1
Meng, H	1
Li, X	1
Lahens, NF	1
Sparks, JA	1
Karlson, EW	1
Weljie, AM	1
Griffin, JL	1
FitzGerald, GA	2
Cheleschi, S	1
Calamia, V	1
Fernandez-Moreno, M	1
Fioravanti, A	1
Blanco, F	1
Choi, J	1
Lee, CY	1
Shin, DY	1
Cooper-DeHoff, RM	1
Angeli, F	1
Trapasso, M	1
Signorotti, S	1
Verdecchia, P	1
Reboldi, G	1
Navarro, SL	1
Herrero, M	1
Martinez, H	1
Ladd, J	1
Lo, E	1
Shelley, D	1
Randolph, TW	1
Lampe, JW	1
Lampe, PD	1
Crivelli, B	1
Bari, E	1
Perteghella, S	1
Catenacci, L	1
Sorrenti, M	1
Mocchi, M	1
Faragò, S	1
Tripodo, G	1
Prina-Mello, A	1
Torre, ML	1
Shao, M	1
Wolski, K	1
Nissen, S	1
Paynter, N	1
Shukla, AK	1
Jhaj, R	1
Gottardi, R	1
Krasselt, M	1
Baerwald, C	1
de Leon-Casasola, OA	1
Dave, M	1
Amin, AR	1
Peng, X	1
Wu, N	1
Chen, SY	1
Yu, X	1
Andrews, JS	1
Novick, D	1
Iyengar, RL	1
Gandhi, S	1
Aneja, A	1
Thorpe, K	1
Razzouk, L	1
Greenberg, J	1
Mosovich, S	1
Farkouh, ME	1
Hirayama, A	1
Tanahashi, N	1
Daida, H	1
Ishiguro, N	1
Chachin, M	1
Sugioka, T	1
Kawai, S	1
Hapca, A	1
Jennings, CG	1
Wei, L	2
Wilson, A	2
MacDonald, TM	2
Mackenzie, IS	2
Peck, Y	1
Ng, LY	1
Goh, JY	1
Gao, C	1
Wang, DA	1
Brereton, N	2
Pennington, B	1
Ekelund, M	1
Akehurst, R	2
Spies, CM	1
Stemmler, E	1
Buttgereit, F	1
Li, Z	1
Meng, D	1
Li, G	1
Xu, J	1
Tian, K	1
Temperilli, F	1
Di Franco, M	1
Massimi, I	1
Guarino, ML	1
Guzzo, MP	1
Valesini, G	1
Frati, L	1
Pulcinelli, FM	1
Danilov, AB	1
Grigorenko, NV	1
Song, GG	1
Seo, YH	1
Choi, SJ	1
Ji, JD	1
Lee, YH	1
Dai, MW	1
Chu, JG	1
Tian, FM	1
Song, HP	1
Wang, Y	1
Zhang, YZ	1
Zhang, L	1
Xu, C	1
Gu, K	1
Yasen, Y	1
Hou, Y	1
Zhuang, Q	1
Bian, Y	1
Wang, W	1
Jiang, J	1
Feng, B	1
Sun, T	1
Lin, J	1
Zhang, M	1
Yan, S	1
Hawkey, CJ	1
Ford, I	1
McMurray, JJV	1
Scheiman, JM	3
Hallas, J	1
Findlay, E	1
Grobbee, DE	1
Hobbs, FDR	1
Ralston, SH	1
Reid, DM	1
Walters, MR	1
Webster, J	1
Ritchie, LD	1
Perez-Gutthann, S	1
Connolly, E	1
Greenlaw, N	1
Janssen, M	1
Timur, UT	1
Welting, TJ	1
Draaisma, G	1
Gijbels, M	1
van Rhijn, LW	1
Nurmohamed, MT	1
Brizuela, NY	1
Montrull, HL	1
Demurtas, SL	1
Meirovich, CI	1
Huh, JE	2
Baek, YH	2
Kim, YJ	1
Lee, JD	3
Choi, DY	2
Park, DS	3
Bessette, L	1
Risebrough, N	1
Mittmann, N	1
Roussy, JP	1
Ho, J	1
Zlateva, G	1
Renda, G	2
Zurro, M	2
Romano, M	1
De Caterina, R	2
Cheung, R	1
Cheng, TT	1
Dong, Y	1
Lin, HY	1
Lai, K	1
Lau, CS	1
Feng, H	1
Parsons, B	1
Rahme, E	2
Bernatsky, S	1
Chan, FK	5
Lanas, A	3
Scheiman, J	1
Nguyen, H	2
Goldstein, JL	8
Kang, M	1
Jung, I	1
Hur, J	1
Kim, SH	1
Lee, JH	1
Kang, JY	1
Jung, KC	1
Kim, KS	1
Yoo, MC	1
Cho, YB	1
Sakamoto, C	1
Soen, S	1
Ferland, CE	1
Laverty, S	1
Beaudry, F	1
Vachon, P	1
Cryer, B	3
Luo, X	2
Assaf, AR	1
Sands, G	1
Mardekian, J	1
Bingham, CO	2
Smugar, SS	3
Wang, H	1
Peloso, PM	1
Gammaitoni, A	1
Ou, YS	1
Tan, C	2
An, H	2
Jiang, DM	1
Quan, ZX	1
Tang, K	2
Luo, XJ	1
Wilcox, CM	2
Peura, D	1
Sands, GH	2
Louder, AM	1
Joshi, AV	1
Ball, AT	1
Cappelleri, JC	1
Deminski, MC	1
Sanchez, RJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
In Vivo Selectivity of Cyclooxygenase Inhibitors in the Oral Surgery Model[NCT00006299]	Phase 2	120 participants	Interventional	1999-12-31	Completed
A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects[NCT01968070]	Phase 1	80 participants (Actual)	Interventional	2013-10-31	Completed
A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216]	Phase 4	24,081 participants (Actual)	Interventional	2006-10-04	Completed
Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function[NCT02507219]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2015-07-31	Completed
Salicylic Augmentation in Depression[NCT03152409]	Phase 2	74 participants (Anticipated)	Interventional	2018-11-15	Recruiting
A Prospective, Randomized, Double-blinded, Multi-center, Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered Orally in Patients With Knee Osteoarthritis[NCT03404479]	Phase 4	90 participants (Anticipated)	Interventional	2018-01-25	Recruiting
A Study to Evaluate Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib Post Total Knee Arthroplasty in Osteoarthritis Patients[NCT02198924]	Phase 4	246 participants (Actual)	Interventional	2014-12-31	Completed
Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's[NCT00447759]	Phase 4	7,297 participants (Actual)	Interventional	2007-06-30	Completed
Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At Hig[NCT00141102]	Phase 4	4,484 participants (Actual)	Interventional	2005-10-31	Completed
Gastrointestinal (GI) Randomized Event And Safety Open-Label NSAID Study (GI-Reasons): A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS) In O[NCT00373685]	Phase 4	8,067 participants (Actual)	Interventional	2006-10-31	Completed
A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee[NCT00092365]	Phase 3	413 participants (Actual)	Interventional	2003-04-01	Completed
A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee[NCT00092352]	Phase 3	395 participants (Actual)	Interventional	2003-04-29	Completed
A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 2)[NCT00092781]	Phase 3	500 participants (Actual)	Interventional	2004-03-01	Completed
A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 1)[NCT00092768]	Phase 3	500 participants (Actual)	Interventional	2004-03-01	Completed
A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoar[NCT00366938]	Phase 3	1,464 participants	Interventional	2003-09-30	Completed
A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoar[NCT00367315]	Phase 3	1,684 participants	Interventional	2003-09-30	Completed
A Phase 3 Double Blinded, Randomized, Placebo Controlled Trial of Proton Pump Inhibitor for the Prevention of Recurrent Ulcer Bleeding in Patients Receiving a COX-2 Inhibitor[NCT00365313]	Phase 3	273 participants	Interventional	2002-08-31	Completed
A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taki[NCT00175032]	Phase 3	1,045 participants (Actual)	Interventional	2003-07-31	Completed
A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in [NCT00145301]	Phase 3	3,036 participants	Interventional	2004-09-30	Completed
Toward Better Outcomes in Osteoarthritis (OA): Finding the Appropriate Role for Nonsteroidal Anti-inflammatory Drugs (NSAIDs)[NCT00000425]	Phase 3	900 participants	Interventional	1996-07-31	Completed
Arthroscopic Surgery Versus Non-surgical Treatment of Osteoarthritis of the Knee[NCT00158431]	Phase 3	186 participants (Actual)	Interventional	1999-01-31	Completed
The Effects of Bariatric Surgery Weight Loss on Knee Pain in Patients With Osteoarthritis of the Knee[NCT00752765]		30 participants (Anticipated)	Observational	2008-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module. (NCT01968070)
Timeframe: Baseline to Study Completion (Up To Day 42)

Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time Curve From Zero to Infinity (AUC 0-∞) of Single Dose LY3127760

Intervention	Participants (Count of Participants)
Part 1: Placebo	0
Part 1: 20 mg LY3127760	0
Part 1: 60 mg LY3127760	0
Part 1: 200 mg LY3127760	0
Part 1: 600 mg LY3127760	0
Part 1: 600 mg LY3127760 (Fasted)	0
Part 1: 900 mg LY3127760	0
Part 2: Placebo	0
Part 2: 20 mg LY3127760	0
Part 2: 60 mg LY3127760	0
Part 2: 200 mg LY3127760	0
Part 2: 300 mg LY3127760	0
Part 2: 400 mg Celecoxib	0

(NCT01968070)
Timeframe: Day 1: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 96, and 144 Hours

PK: Area Under the Concentration Versus Time Curve During One Dosing Interval [AUC-tau (τ)] of Multiple Doses LY3127760

Intervention	nanograms•hour/milliliter (ng•hr/mL) (Geometric Mean)
Part 1: 20 mg LY3127760	NA
Part 1: 60 mg LY3127760	3010
Part 1: 200 mg LY3127760	17200
Part 1: 600 mg LY3127760	40000
Part 1: 600 mg LY3127760 (Fasted)	47400
Part 1: 900 mg LY3127760	71900

AUC-tau (τ) where τ is 24-hours for the 20 mg, 60 mg, and 200 mg cohorts, and 12-hours for the 300 mg cohort. (NCT01968070)
Timeframe: Day 28: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, and 24 Hours

PK: Cmax of Multiple Doses LY3127760

Intervention	ng•hr/ml (Geometric Mean)
Part 2: 20 mg LY3127760	1020
Part 2: 60 mg LY3127760	4350
Part 2: 200 mg LY3127760	11300
Part 2: 300 mg LY3127760	19700

(NCT01968070)
Timeframe: Post last dose on Day 28: 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 72, and 168 Hours

PK: Maximum Observed Concentration (Cmax) of Single Dose LY3127760

Intervention	ng/mL (Geometric Mean)
Part 2: 20 mg LY3127760	301
Part 2: 60 mg LY3127760	1210
Part 2: 200 mg LY3127760	3650
Part 2: 300 mg LY3127760	6170

(NCT01968070)
Timeframe: Day 1: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 96, and 144 Hours

PK: Time of Maximum Observed Concentration (Tmax) of Single Dose LY3127760

Intervention	nanograms/milliliter (ng/mL) (Geometric Mean)
Part 1: 20 mg LY3127760	264
Part 1: 60 mg LY3127760	890
Part 1: 200 mg LY3127760	3880
Part 1: 600 mg LY3127760	10300
Part 1: 600 mg LY3127760 (Fasted)	18900
Part 1: 900 mg LY3127760	21600

(NCT01968070)
Timeframe: Day 1: -1, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 96, and 144 Hours

PK: Tmax of Multiple Doses LY3127760

Intervention	Hour (Median)
Part 1: 20 mg LY3127760	2.00
Part 1: 60 mg LY3127760	2.00
Part 1: 200 mg LY3127760	2.00
Part 1: 600 mg LY3127760	2.00
Part 1: 600 mg LY3127760 (Fasted)	1.00
Part 1: 900 mg LY3127760	1.50

(NCT01968070)
Timeframe: Post-last dose on Day 28: 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 72, and 168 Hours

Change From Baseline in Patient's Assessment of Arthritis Pain (VAS)

Intervention	hour (Median)
Part 2: 20 mg LY3127760	2.00
Part 2: 60 mg LY3127760	1.65
Part 2: 200 mg LY3127760	2.00
Part 2: 300 mg LY3127760	2.00

"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months

The First Occurrence of a Major Adverse Cardiovascular Events (MACE)

Intervention	Number of participants (Mean)
	Baseline (ITT) N= 8014, 8001, 7928	Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325	Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149	Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740	Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159	Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846	Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246	Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785	Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086	Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635	Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439	Baseline (MITT) N=7974, 7954, 7894	Change-Baseline to Mon1 MITT N=7372, 7367, 7321	Change-Baseline to Mon2 MITT N=7170, 7078, 7142	Change-Baseline to Mon4 MITT N=6772, 6686, 6732	Change-Baseline to Mon8 MITT N=6224, 6128, 6155	Change-Baseline to Mon12 MITT N=5787, 5689, 5844	Change-Baseline to Mon18 MITT N=5305, 5175, 5242	Change-Baseline to Mon24 MITT N=4815, 4769, 4782	Change-Baseline to Mon30 MITT N=4139, 4067, 4085	Change-Baseline to Mon36 MITT N=3691, 3623, 3635	Change-Baseline to Mon42 MITT N=3468, 3404, 3438
Celecoxib	54.0	-8.2	-10.5	-11.4	-11.7	-11.0	-11.3	-11.3	-10.5	-10.1	-11.4	54.0	-8.2	-10.5	-11.4	-11.7	-11.0	-11.3	-11.4	-10.5	-10.2	-11.4
Ibuprofen	54.1	-9.0	-10.6	-11.7	-12.1	-11.6	-11.3	-11.5	-11.2	-10.7	-11.1	54.1	-9.0	-10.6	-11.7	-12.1	-11.6	-11.3	-11.5	-11.2	-10.7	-11.1
Naproxen	54.1	-9.9	-11.1	-12.3	-12.1	-11.9	-11.7	-11.4	-11.3	-11.6	-12.1	54.1	-9.9	-11.1	-12.3	-12.1	-11.9	-11.7	-11.3	-11.3	-11.6	-12.1

MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months

The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC).

Intervention	Percentage of Participants (Number)
	ITT (N = 8072, 8040, 7969)	MITT (N = 8030, 7990, 7933)
Celecoxib	4.2	3.1
Ibuprofen	4.8	3.6
Naproxen	4.3	3.2

APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months

The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE)

Intervention	Percentage of Partcipants (Number)
	ITT (N = 8072, 8040, 7969)	MITT (N = 8030, 7990, 7933)
Celecoxib	2.3	1.7
Ibuprofen	2.7	1.9
Naproxen	2.5	1.8

CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months

Dose-dependent Differences in the BOLD Response to fMRI Tasks in the Amygdala

Intervention	Percentage of Participants (Number)
	ITT (N = 8072, 8040, 7969)	MITT (N = 8030, 7990, 7933)
Celecoxib	0.7	0.3
Ibuprofen	0.9	0.7
Naproxen	0.7	0.7

Change in amygdala activation following administration of placebo, 200mg of ibuprofen or 600mg of ibuprofen (NCT02507219)
Timeframe: 3-6 weeks

Change From Baseline in C-Reactive Protein to Month 6/ET

Change From Baseline in Ferretin to Month 6/ET

Change From Baseline in Hematocrit at Month 6/ET

Change From Baseline in Hemoglobin at Month 6/ET

Change From Baseline in Iron Binding Capacity to Month 6/ET

Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET)

Intervention	percent signal change (Mean)
	Left amygdala	Right amygdala
Ibuprofen, 200mg	0.21	0.23
Ibuprofen, 600mg	0.23	0.17
Placebo	0.20	0.23

Intervention	mg/dL (Least Squares Mean)
Celecoxib	0.058
Oral Diclofenac Plus Omeprazole	0.073

Intervention	ug/dL (Least Squares Mean)
Celecoxib	-3.396
Oral Diclofenac Plus Omeprazole	-1.990

Intervention	percent (Least Squares Mean)
Celecoxib	-0.306
Oral Diclofenac Plus Omeprazole	-1.425

Intervention	grams (g)/deciliter (dL) (Least Squares Mean)
Celecoxib	-0.017
Oral Diclofenac Plus Omeprazole	-0.423

Intervention	microgram (ug)/dL (Least Squares Mean)
Celecoxib	2.517
Oral Diclofenac Plus Omeprazole	1.952

"Subjects rated response to question: Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today? using a 1 to 5 grading scale where 1=very good and 5=very poor." (NCT00141102)
Timeframe: Month 6/Early Termination (ET)

Number of Subjects Alive at the Post Trial Interview

Intervention	scores on a scale (Least Squares Mean)
Celecoxib	0.754
Oral Diclofenac Plus Omeprazole	0.773

Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose

Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview

Intervention	participants (Number)
Celecoxib	2018
Oral Diclofenac Plus Omeprazole	2023

Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose

Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin

Intervention	participants (Number)
Celecoxib	82
Oral Diclofenac Plus Omeprazole	79

A clinically significant decrease from baseline was defined as a fall in hematocrit > = 10 percentage points and/or hemoglobin > = 2 g/dL. (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)

Intervention	participants (Number)
Celecoxib	45
Oral Diclofenac Plus Omeprazole	123

CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)

Intervention	participants (Number)
Celecoxib	20
Oral Diclofenac Plus Omeprazole	81

CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects With Moderate to Severe Abdominal Symptoms

Intervention	participants (Number)
Celecoxib	25
Oral Diclofenac Plus Omeprazole	92

"Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms." (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects With SUs

Intervention	participants (Number)
Celecoxib	132
Oral Diclofenac Plus Omeprazole	162

Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects Withdrawn Due to GI Adverse Events (AEs)

Intervention	participants (Number)
Celecoxib	5
Oral Diclofenac Plus Omeprazole	11

"GI AEs were defined using MedDRA SOC Gastrointestinal Disorders but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions." (NCT00141102)
Timeframe: 6 month treatment duration

Change From Baseline in Hepatic Measures of GGT, AST or ALT to Month 6/ET

Number of Subjects With CSULGIEs by History of GD Ulceration

Intervention	participants (Number)
Celecoxib	114
Oral Diclofenac Plus Omeprazole	167

Intervention	IU/L (Least Squares Mean)
	GGT	AST	ALT
Celecoxib	-2.689	-0.901	-1.151
Oral Diclofenac Plus Omeprazole	7.455	1.490	5.213

Number of Subjects With Hepatic AEs in Gamma Glutamyl-Transferase (GGT), Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) of 3 Times the Upper Limit of Normal (ULN)

Intervention	participants (Number)
	History of GD Ulceration (n=395, 400)	No History of GD Ulceration (n=1843, 1846)
Celecoxib	7	13
Oral Diclofenac Plus Omeprazole	13	68

GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males. (NCT00141102)
Timeframe: 6 month treatment duration

Change From Baseline Hb at Week 24

Change From Baseline Hct at Week 24

Hematocrit (Hct) at Baseline

Hemoglobin (Hb) at Baseline

Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs)

Intervention	participants (Number)
	GGT	AST	ALT
Celecoxib	26	8	13
Oral Diclofenac Plus Omeprazole	86	12	27

Intervention	g/dL (Least Squares Mean)
Celecoxib	-0.109
nsNSAIDs	-0.241

Intervention	Percent (Least Squares Mean)
Celecoxib	-0.330
nsNSAIDs	-0.716

Intervention	Percent (Mean)
Celecoxib	40.8
nsNSAIDs	40.9

Intervention	gram per deciliter (g/dL) (Mean)
Celecoxib	13.6
nsNSAIDs	13.6

GI AEs defined using MedDRA SOC 'Gastrointestinal Disorders' but excluding HLGT's: Benign Neoplasms Gastrointestinal, Dental and Gingival Conditions, Oral Soft Tissue Conditions, Salivary Gland Conditions and Tongue Conditions (NCT00373685)
Timeframe: Baseline through week 24 or ET

Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)

Intervention	Percentage of participants (Number)
Celecoxib	2.8
nsNSAIDs	3.0

CSULGIE defined as any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; acute gastrointestinal (GI) hemorrhage of unknown origin; small bowel obstruction; clinically significant anemia/blood loss of defined GI origin or presumed occult GI origin. (NCT00373685)
Timeframe: Baseline through week 24 or Early Termination (ET)

Percentage of Participants With Moderate to Severe Abdominal Symptoms

Intervention	Percentage of participants (Number)
Celecoxib	1.3
nsNSAIDs	2.4

"Abdominal symptoms coded using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) 'Gastrointestinal Disorders' high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms; where moderate indicated the gastrointestinal adverse event (GI AE) interfered to some extent with the participants' usual function and severe indicated the GI AE interfered significantly with participants' usual function." (NCT00373685)
Timeframe: Baseline through week 24 or ET

Percentage of Participants With Positive Blood Fecal Occult

Intervention	Percentage of participants (Number)
Celecoxib	2.3
nsNSAIDs	3.4

Positive blood fecal occult; blood in feces that is not visibly apparent (NCT00373685)
Timeframe: Week 24 or ET

Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Amount of Pain Relief

Intervention	Percentage of participants (Number)
Celecoxib	1.1
nsNSAIDs	1.4

Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the amount of pain relief medication provided, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15. (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET

Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Duration of Pain Relief

Intervention	Percentage of participants (Number)
	Baseline (n=3888, 3905)	Week 8 (n=3185, 3203)	Week 16 (n=2783, 2778)	Week 24 or ET (n=3385, 3362)	Week 24/LOCF (n=3671, 3653)
Celecoxib	41.4	77.4	80.5	74.0	74.0
nsNSAIDs	40.5	69.2	74.5	71.3	70.8

Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy, subscale for duration of pain relief provided by medication, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15. (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET

Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Time to Pain Relief

Intervention	Percentage of participants (Number)
	Baseline (n=3886, 3905)	Week 8 (n=3182, 3202)	Week 16 (n=2780,2778)	Week 24 or ET (n=3383,3361)	Week 24/LOCF (n=3671, 3653)
Celecoxib	37.8	75.4	77.8	72.2	72.2
nsNSAIDs	36.6	66.8	71.6	68.8	68.2

Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the time it took medication to work, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15. (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET

Percentage of Participants Satisfied With Efficacy of Current Pain Medication Overall

Intervention	Percentage of participants (Number)
	Baseline (n=3890, 3905)	Week 8 (n=3185, 3202)	Week 16 (n=2784,2777)	Week 24 or ET (n=3386,3362)	Week 24/LOCF (n=3672, 3653)
Celecoxib	43.2	80.2	83.2	76.2	76.0
nsNSAIDs	43.7	71.6	77.7	73.8	73.3

Percentage of participants who reported Very Satisfied or Satisfied with current pain medication question on the Patient Treatment Satisfaction Scale (PTSS), scale ranged from Very Satisfied (1) to Very Dissatisfied (5). (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET

Percentage of Participants With Clinically Significant Decrease in Hct and/or Hb From Baseline

Intervention	Percentage of participants (Number)
	Baseline (n=3887, 3904)	Week 8 (n=3181, 3199)	Week 16 (n=2784, 2772)	Week 24 or ET (n=3383, 3361)	Week 24/LOCF (n=3672, 3651)
Celecoxib	39.8	78.5	81.9	74.6	74.5
nsNSAIDs	38.0	69.5	74.6	70.8	70.3

Clinically significant decrease in Hct (greater than or equal to 10 percent [≥10%]) and/or decrease in Hb (≥ 2 g/dL). (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET

Percentage of Participants With Non-study Medication Utilization

Intervention	Percentage of participants (Number)
	Week 8 (n= 3043, 3086)	Week 16 (n=2687, 2675)	Week 24 (n=3278, 3207)	Week 24 LOCF (n=3604, 3574)
Celecoxib	0.7	0.8	0.9	1.8
nsNSAIDs	0.9	1.6	1.5	2.9

Non-study medication utilization associated with initial treatment defined as narcotic analgesics and acetaminophen use. (NCT00373685)
Timeframe: Baseline through week 24 or ET

Percentage of Participants With Proton Pump Inhibitor (PPI) and Other Gastric Protective Drug Utilization

Intervention	Percentage of participants (Number)
	Acetaminophen	Acetylsalicylic acid (ASA)	NSAIDs	Opioids
Celecoxib	6.8	3.5	12.8	14.2
nsNSAIDs	6.5	3.0	13.3	15.6

PPI and other gastric protective drug (defined as Histamine-2 receptor antagonists [H2RA], misoprostol, sucralfate, and others such as antacids) utilization. (NCT00373685)
Timeframe: Baseline through week 24 or ET

Article	Year
Recent advances in polysaccharides for osteoarthritis therapy. European journal of medicinal chemistry, 2017, Oct-20, Volume: 139 Topics: Animals; Carbohydrate Conformation; Humans; Osteoarthritis; Polysaccharides	2017
Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis. European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:22 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Network Meta-Analysis; Osteo	2021
Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis. PloS one, 2021, Volume: 16, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular System; Celecoxib; Hu	2021
Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis. British journal of clinical pharmacology, 2022, Volume: 88, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Opioid-Related Disorders; Osteoarthritis	2022
Celecoxib for osteoarthritis. British journal of community nursing, 2019, Oct-02, Volume: 24, Issue:10 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Communi	2019
Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. The American journal of medicine, 2019, Volume: 132, Issue:2 Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; Humans; Hyp	2019
Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:11 Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; Drug Combin	2018
Celecoxib for the treatment of musculoskeletal arthritis. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:14 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib;	2019
Opioids for chronic pain: new evidence, new strategies, safe prescribing. The American journal of medicine, 2013, Volume: 126, Issue:3 Suppl 1 Topics: Age Factors; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Pain; C	2013
[An antinociceptive effect of chondroprotectors: a myth or a reality?]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:9 Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; Celecoxib; Chondroitin Sulf	2015
Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. Zeitschrift fur Rheumatologie, 2016, Volume: 75, Issue:5 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bayes Theorem; Celecoxib; Dose-Response Relations	2016
Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Medicine, 2016, Volume: 95, Issue:20 Topics: Abdominal Pain; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Diarrhea; Dyspepsia; Headache;	2016
Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion, 2011, Volume: 83, Issue:1-2 Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Japan; Osteoarthritis; Pyrazo	2011
Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis research & therapy, 2011, Volume: 13, Issue:5 Topics: Animals; Antirheumatic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Evidence-	2011
Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs, 2011, Dec-24, Volume: 71, Issue:18 Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Hum	2011
Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. Expert review of pharmacoeconomics & outcomes research, 2012, Volume: 12, Issue:4 Topics: Arthritis, Rheumatoid; Celecoxib; Cost of Illness; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitor	2012
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective. Spine, 2013, May-15, Volume: 38, Issue:11 Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; C	2013
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ (Clinical research ed.), 2002, Sep-21, Volume: 325, Issue:7365 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I	2002
Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective. The American journal of managed care, 2002, Volume: 8, Issue:17 Suppl Topics: Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibito	2002
[The future of peptic ulcer disease without Helicobacter]. Praxis, 2003, Mar-19, Volume: 92, Issue:12 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin	2003
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib;	2003
[Interactions of nonsteroid anti-inflammatory drugs with inhibitors of angiotensin-converting enzyme in patients with rheumatic diseases (a review)]. Terapevticheskii arkhiv, 2003, Volume: 75, Issue:5 Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheuma	2003
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert opinion on drug safety, 2002, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Ce	2002
Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us? Rheumatic diseases clinics of North America, 2003, Volume: 29, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibitors; Di	2003
[Clinical pharmacology of the selective COX-2 inhibitors]. Der Orthopade, 2003, Volume: 32, Issue:12 Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis	2003
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford, England), 2004, Volume: 43 Suppl 1 Topics: Acetates; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo	2004
Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis research & therapy, 2005, Volume: 7, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Drug Industry; Drug Toler	2005
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Current topics in medicinal chemistry, 2005, Volume: 5, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cy	2005
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs]. MMW Fortschritte der Medizin, 2005, Aug-04, Volume: 147, Issue:31-32 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis,	2005
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis research & therapy, 2007, Volume: 9, Issue:1 Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis;	2007
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis research & therapy, 2007, Volume: 9, Issue:1 Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis;	2007
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis research & therapy, 2007, Volume: 9, Issue:1 Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis;	2007
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis research & therapy, 2007, Volume: 9, Issue:1 Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis;	2007
Clinical inquiries. Do COX-2 inhibitors worsen renal function? The Journal of family practice, 2007, Volume: 56, Issue:11 Topics: Arthritis, Rheumatoid; Celecoxib; Contraindications; Cyclooxygenase 2 Inhibitors; Humans; Kidney; La	2007
Clinical use and pharmacological properties of selective COX-2 inhibitors. European journal of clinical pharmacology, 2008, Volume: 64, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibito	2008
Compositions for treatment of cancer and inflammation. Recent patents on anti-cancer drug discovery, 2008, Volume: 3, Issue:1 Topics: Apoptosis; Celecoxib; Cell Proliferation; Colorectal Neoplasms; Curcumin; Cyclooxygenase 2 Inhibitor	2008
Pain management in osteoarthritis: the role of COX-2 inhibitors. The Journal of rheumatology. Supplement, 1997, Volume: 49 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit	1997
COX 2-selective NSAIDs: biology, promises, and concerns. Cleveland Clinic journal of medicine, 1999, Volume: 66, Issue:5 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Child;	1999
Cyclooxygenase-2 specificity and its clinical implications. The American journal of medicine, 1999, May-31, Volume: 106, Issue:5B Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Clinical Trial	1999
Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clinical therapeutics, 1999, Volume: 21, Issue:9 Topics: Animals; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenas	1999
Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. The Journal of the American Osteopathic Association, 1999, Volume: 99, Issue:11 Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox	1999
Osteoarthritis: current concepts in diagnosis and management. American family physician, 2000, Mar-15, Volume: 61, Issue:6 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diagnosis	2000
Osteoarthritis: current concepts in diagnosis and management. American family physician, 2000, Mar-15, Volume: 61, Issue:6 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diagnosis	2000
Osteoarthritis: current concepts in diagnosis and management. American family physician, 2000, Mar-15, Volume: 61, Issue:6 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diagnosis	2000
Osteoarthritis: current concepts in diagnosis and management. American family physician, 2000, Mar-15, Volume: 61, Issue:6 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diagnosis	2000
Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs, 2000, Volume: 59, Issue:4 Topics: Acute Disease; Animals; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Electron Transp	2000
[New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results]. Lakartidningen, 2000, Jun-14, Volume: 97, Issue:24 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trial	2000
Selective inhibitors of COX-2--are they safe for the stomach? Scandinavian journal of gastroenterology, 2000, Volume: 35, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox	2000
Efficacy of cyclooxygenase-2-specific inhibitors. The American journal of medicine, 2001, Feb-19, Volume: 110 Suppl 3A Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge	2001
[Pharma-clinics. The drug of the month. Celecoxib (Celebrex)]. Revue medicale de Liege, 2001, Volume: 56, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors	2001
Celecoxib clinical profile. Rheumatology (Oxford, England), 2000, Volume: 39 Suppl 2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec	2000
The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. American journal of therapeutics, 2000, Volume: 7, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trial	2000
Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. American journal of therapeutics, 2000, Volume: 7, Issue:3 Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal	2000
Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgraduate medical journal, 2001, Volume: 77, Issue:910 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Drug Induced Liver Injury; Ch	2001
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis. Hand clinics, 2001, Volume: 17, Issue:2 Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumat	2001
[Celebrex: confirmed effectiveness and safety (new data)]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:5 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygena	2001
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Current pharmaceutical design, 2002, Volume: 8, Issue:12 Topics: Acetaminophen; Analgesia; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase	2002
[A critical evaluation of side effect data on COX-2 inhibitors]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002, Feb-20, Volume: 122, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors	2002
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use? Current opinion in rheumatology, 2002, Volume: 14, Issue:3 Topics: Arthritis; Aspirin; Cardiovascular System; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors;	2002
An update on specific COX-2 inhibitors: the COXIBs. Bulletin on the rheumatic diseases, 2001, Volume: 50, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox	2001

Article	Year
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients. Osteoarthritis and cartilage, 2023, Volume: 31, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac	2023
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients. Osteoarthritis and cartilage, 2023, Volume: 31, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac	2023
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients. Osteoarthritis and cartilage, 2023, Volume: 31, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac	2023
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients. Osteoarthritis and cartilage, 2023, Volume: 31, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac	2023
A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis. PloS one, 2020, Volume: 15, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Double-Blind Method; Es	2020
Praxis, 2017, Volume: 106, Issue:8 Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Drug Therapy,	2017
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. The American journal of medicine, 2017, Volume: 130, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibito	2017
LY3127760, a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles. Clinical and translational science, 2018, Volume: 11, Issue:1 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Celecoxib; Double-	2018
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) European heart journal, 2017, Nov-21, Volume: 38, Issue:44 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Coronary	2017
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec	2018
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspi	2018
[EFFICACY OF SEQUENTIAL TREATMENT WITH ADDUCTOR CANAL NERVE BLOCK AND CYCLOOXYGENASE 2 SELECTIVE INHIBITOR AFTER TOTAL KNEE ARTHROPLASTY]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2016, Sep-08, Volume: 30, Issue:9 Topics: Analgesics, Opioid; Arthroplasty, Replacement, Knee; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans;	2016
Differences in Serum Biomarkers Between Combined Glucosamine and Chondroitin Versus Celecoxib in a Randomized, Double-blind Trial in Osteoarthritis Patients. Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2020, Volume: 19, Issue:2 Topics: Aged; Anti-Inflammatory Agents; Biomarkers; Celecoxib; Chemokine CCL20; Chondroitin; Colony-Stimulat	2020
Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:8 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec	2019
Utilization of duloxetine and celecoxib in osteoarthritis patients. Current medical research and opinion, 2013, Volume: 29, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Celecoxib; Cyclooxygenase 2 Inhibitors; Dulo	2013
NSAIDs are associated with lower depression scores in patients with osteoarthritis. The American journal of medicine, 2013, Volume: 126, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub	2013
NSAIDs are associated with lower depression scores in patients with osteoarthritis. The American journal of medicine, 2013, Volume: 126, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub	2013
NSAIDs are associated with lower depression scores in patients with osteoarthritis. The American journal of medicine, 2013, Volume: 126, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub	2013
NSAIDs are associated with lower depression scores in patients with osteoarthritis. The American journal of medicine, 2013, Volume: 126, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub	2013
Efficacy and safety of Postoperative Intravenous Parecoxib sodium Followed by ORal CElecoxib (PIPFORCE) post-total knee arthroplasty in patients with osteoarthritis: a study protocol for a multicentre, double-blind, parallel-group trial. BMJ open, 2016, 09-08, Volume: 6, Issue:9 Topics: Administration, Oral; Arthroplasty, Replacement, Knee; Celecoxib; China; Cyclooxygenase 2 Inhibitors	2016
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). European heart journal, 2017, Jun-14, Volume: 38, Issue:23 Topics: Acute Coronary Syndrome; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celec	2017
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. British journal of clinical pharmacology, 2010, Volume: 69, Issue:3 Topics: Aged; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Humans; Ibuprofen;	2010
Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. International journal of rheumatic diseases, 2010, Volume: 13, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; China; Comorbidity; Cy	2010
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet (London, England), 2010, Jul-17, Volume: 376, Issue:9736 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib;	2010
Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo. Pain medicine (Malden, Mass.), 2011, Volume: 12, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitor	2011
Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials. Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:7 Topics: Adult; Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celeco	2011
Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; D	2012
The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Modern rheumatology, 2013, Volume: 23, Issue:6 Topics: Alanine; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; E	2013
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. The American journal of gastroenterology, 2013, Volume: 108, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibi	2013
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. The American journal of cardiology, 2002, Nov-01, Volume: 90, Issue:9 Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure;	2002
Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis. Proceedings of the Western Pharmacology Society, 2002, Volume: 45 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Celecoxib; Cholestyramine Resin;	2002
Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Current medical research and opinion, 2003, Volume: 19, Issue:5 Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Female; Health Status; Humans; Lactones; Logistic Models	2003
A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs, 2003, Volume: 63 Suppl 1 Topics: Adult; Aged; Analysis of Variance; Celecoxib; Double-Blind Method; Female; Humans; Knee; Lactones; M	2003
Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis and rheumatism, 2003, Volume: 48, Issue:11 Topics: Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Lactones; Male; Middle Ag	2003
Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. The Journal of rheumatology, 2004, Volume: 31, Issue:1 Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors;	2004
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:3 Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anti	2004
Tramadol pharmacokinetics and its possible interactions with cyclooxygenase 2-selective nonsteroidal anti-inflammatory drugs. Clinical pharmacology and therapeutics, 2004, Volume: 75, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relatio	2004
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Jul-01, Volume: 61, Issue:13 Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge	2004
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. The Journal of rheumatology, 2004, Volume: 31, Issue:9 Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male;	2004
Lumiracoxib. Drugs, 2004, Volume: 64, Issue:19 Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Doubl	2004
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. The Journal of rheumatology, 2005, Volume: 32, Issue:1 Topics: Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method	2005
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Archives of internal medicine, 2005, Jan-24, Volume: 165, Issue:2 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blood Pressure Determi	2005
[Celecoxib and Tramadol as an alternative osteoarthrosis therapy in patients with NSAID gastropathy]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2004, Issue:5 Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; D	2004
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current medical research and opinion, 2006, Volume: 22, Issue:1 Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Male; Middle Ag	2006
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current medical research and opinion, 2006, Volume: 22, Issue:1 Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Male; Middle Ag	2006
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current medical research and opinion, 2006, Volume: 22, Issue:1 Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Male; Middle Ag	2006
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current medical research and opinion, 2006, Volume: 22, Issue:1 Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Male; Middle Ag	2006
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. The American journal of medicine, 2006, Volume: 119, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Bl	2006
A randomized database study in general practice yielded quality data but patient recruitment in routine consultation was not practical. Journal of clinical epidemiology, 2006, Volume: 59, Issue:5 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Databases, Factual; Diclofenac; Family Pr	2006
Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:1 Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, N	2007
A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Annals of the rheumatic diseases, 2007, Volume: 66, Issue:1 Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemotherapy, Adjuva	2007
Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. Current medical research and opinion, 2006, Volume: 22, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Double-Blind Method; Female; Humans; Lactones; Male; Midd	2006
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 In	2007
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 In	2007
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 In	2007
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 In	2007
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney international, 2006, Volume: 70, Issue:8 Topics: Acid-Base Equilibrium; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis,	2006
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clinical pharmacology and therapeutics, 2006, Volume: 80, Issue:3 Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Celecoxib; Double-Blind Method; Drug Adminis	2006
Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? Journal of hypertension, 2006, Volume: 24, Issue:10 Topics: Aged; Aldosterone; Blood Pressure; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Femal	2006
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis research & therapy, 2007, Volume: 9, Issue:1 Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis;	2007
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis research & therapy, 2007, Volume: 9, Issue:1 Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis;	2007
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis research & therapy, 2007, Volume: 9, Issue:1 Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis;	2007
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis research & therapy, 2007, Volume: 9, Issue:1 Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis;	2007
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet (London, England), 2007, May-12, Volume: 369, Issue:9573 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibito	2007
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2007, Volume: 5, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2007
[Changes in quality of life in patients with osteoarthritis treated with celecoxib: the Qualice study]. Presse medicale (Paris, France : 1983), 2008, Volume: 37, Issue:4 Pt 1 Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Female; Humans	2008
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC musculoskeletal disorders, 2008, Mar-07, Volume: 9 Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury	2008
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis and rheumatism, 1998, Volume: 41, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase Inhibitors	1998
Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy, 1999, Volume: 19, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dose-Response Re	1999
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clinic proceedings, 1999, Volume: 74, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2	1999
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?]. Presse medicale (Paris, France : 1983), 2000, Mar-11, Volume: 29, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi	2000
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. The Journal of rheumatology, 2000, Volume: 27, Issue:8 Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyg	2000
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, Sep-13, Volume: 284, Issue:10 Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin;	2000
Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. The journals of gerontology. Series A, Biological sciences and medical sciences, 2001, Volume: 56, Issue:3 Topics: Aged; Aged, 80 and over; Aging; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Female; H	2001
[Effectiveness and tolerance of celebrex in osteoarthrosis (data of a Russian study)]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Male;	2001
Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind	2002

Article	Year
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). Journal of medicinal chemistry, 1997, Apr-25, Volume: 40, Issue:9 Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Carrageenan; Celecoxib; Cyclooxygenase 1; C	1997
Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. Journal of medicinal chemistry, 2013, Apr-25, Volume: 56, Issue:8 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cy	2013
SH2 Domain-Containing Phosphatase 2 Inhibition Attenuates Osteoarthritis by Maintaining Homeostasis of Cartilage Metabolism via the Docking Protein 1/Uridine Phosphorylase 1/Uridine Cascade. Arthritis & rheumatology (Hoboken, N.J.), 2022, Volume: 74, Issue:3 Topics: Animals; Cartilage, Articular; Celecoxib; Chondrocytes; Chondrogenesis; Cyclooxygenase 2 Inhibitors;	2022
Celecoxib nanocrystal-loaded dissolving microneedles with highly efficient for osteoarthritis treatment. International journal of pharmaceutics, 2022, Sep-25, Volume: 625 Topics: Celecoxib; Drug Delivery Systems; Humans; Microinjections; Nanoparticles; Needles; Osteoarthritis; S	2022
Novel Formulation Approaches used for the Management of Osteoarthritis: A Recent Review. Current drug delivery, 2023, Volume: 20, Issue:7 Topics: Animals; Celecoxib; Female; Hydrogels; Male; Osteoarthritis; Pain; Rats; Rats, Inbred Lew	2023
Inhibition of PGE2 in Subchondral Bone Attenuates Osteoarthritis. Cells, 2022, 09-05, Volume: 11, Issue:17 Topics: Animals; Capsaicin; Cartilage, Articular; Celecoxib; Dinoprostone; Humans; Mice; Mice, Knockout; Ost	2022
Intra-articular multifunctional celecoxib loaded hyaluronan nanocapsules for the suppression of inflammation in an osteoarthritic rat model. International journal of pharmaceutics, 2020, Jun-15, Volume: 583 Topics: Animals; Arthritis, Experimental; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Carriers; Drug Compou	2020
Consensi --a fixed dose combination of amlodipine and celecoxib. The Medical letter on drugs and therapeutics, 2020, Mar-09, Volume: 62, Issue:1593 Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Celecoxib; Cyclooxygenase 2 Inhibitor	2020
Nano wet milled celecoxib extended release microparticles for local management of chronic inflammation. International journal of pharmaceutics, 2020, Nov-15, Volume: 589 Topics: Celecoxib; Drug Liberation; Humans; Inflammation; Lactic Acid; Osteoarthritis; Particle Size	2020
A hybrid platform featuring nanomagnetic ligand fishing for discovering COX-2 selective inhibitors from aerial part of Saussurea laniceps Hand.-Mazz. Journal of ethnopharmacology, 2021, May-10, Volume: 271 Topics: Animals; Arthritis, Experimental; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor	2021
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. Cells, 2021, 03-19, Volume: 10, Issue:3 Topics: Animals; Arthritis, Experimental; Celecoxib; Chondrocytes; Diabetes Mellitus, Type 2; Disease Models	2021
Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation. Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:11 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Celecoxib; Drug Combinations; Humans; Hypertens	2021
Evaluation of cardiovascular risk associated with SKI306X use in patients with osteoarthritis and rheumatoid arthritis. Journal of ethnopharmacology, 2017, Jul-31, Volume: 207 Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular D	2017
[Cognitive-cytokine effect of nonsteroidal antiinflammatory drugs in the therapy of elderly patients with osteoarthritis]. Advances in gerontology = Uspekhi gerontologii, 2017, Volume: 30, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition; Cognition Disorders; Cytokines;	2017
NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives? Scandinavian journal of pain, 2017, Volume: 16 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Ibuprofen; Naproxen; Network	2017
Mori Folium water extract alleviates articular cartilage damages and inflammatory responses in monosodium iodoacetate‑induced osteoarthritis rats. Molecular medicine reports, 2017, Volume: 16, Issue:4 Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Dinoprostone; Disease Models, Animal; Down-Regu	2017
Effects of oral glucosamine hydrochloride and mucopolysaccharide protein in a rabbit model of osteoarthritis. International journal of rheumatic diseases, 2018, Volume: 21, Issue:3 Topics: Administration, Oral; Animals; Anterior Cruciate Ligament; Apoptosis; Cartilage, Articular; Celecoxi	2018
Controlled release of celecoxib inhibits inflammation, bone cysts and osteophyte formation in a preclinical model of osteoarthritis. Drug delivery, 2018, Volume: 25, Issue:1 Topics: Animals; Anterior Cruciate Ligament; Biocompatible Materials; Bone and Bones; Celecoxib; Cyclooxygen	2018
Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs. Circulation, 2018, 11-20, Volume: 138, Issue:21 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Blood Pressure; Blood Urea Nitrogen; Car	2018
In vitro comprehensive analysis of VA692 a new chemical entity for the treatment of osteoarthritis. International immunopharmacology, 2018, Volume: 64 Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cells, Cultured; Chondrocytes; Cycloo	2018
Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10. Scientific reports, 2018, 09-14, Volume: 8, Issue:1 Topics: Anilides; Animals; Cartilage; Cartilage, Articular; Celecoxib; Chondrocytes; Chondrogenesis; Cytokin	2018
Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2019, Volume: 137 Topics: Anti-Inflammatory Agents; Antioxidants; Celecoxib; Cell Survival; Cells, Cultured; Curcumin; Drug De	2019
Consensi: Is it a conscientious combination? British journal of clinical pharmacology, 2019, Volume: 85, Issue:5 Topics: Amlodipine; Antihypertensive Agents; Arthralgia; Blood Pressure; Celecoxib; Clinical Trials as Topic	2019
Load-induced osteoarthritis on a chip. Nature biomedical engineering, 2019, Volume: 3, Issue:7 Topics: Cartilage; Celecoxib; Cellular Microenvironment; Cytokines; Gene Expression Profiling; Humans; Lab-O	2019
Yin-Yang regulation of prostaglandins and nitric oxide by PGD2 in human arthritis: reversal by celecoxib. Immunology letters, 2013, Volume: 152, Issue:1 Topics: Celecoxib; Cells, Cultured; Chondrocytes; Dinoprost; Dinoprostone; Humans; Inflammation Mediators; I	2013
Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cele	2014
Effectiveness of newspaper advertising for patient recruitment into a clinical trial. British journal of clinical pharmacology, 2014, Volume: 77, Issue:6 Topics: Advertising; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Humans; Newspapers as Topic	2014
A three-dimensionally engineered biomimetic cartilaginous tissue model for osteoarthritic drug evaluation. Molecular pharmaceutics, 2014, Jul-07, Volume: 11, Issue:7 Topics: Animals; Apoptosis; Biomimetics; Cartilage, Articular; Celecoxib; Cell Differentiation; Cell Line; C	2014
A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. Journal of medical economics, 2014, Volume: 17, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibito	2014
How to mechanistically explain the CONDOR study data. Medical hypotheses, 2015, Volume: 84, Issue:1 Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Intestinal Mucosa	2015
Celecoxib Combined with Diacerein Effectively Alleviates Osteoarthritis in Rats via Regulating JNK and p38MAPK Signaling Pathways. Inflammation, 2015, Volume: 38, Issue:4 Topics: Animals; Anthraquinones; Celecoxib; Drug Therapy, Combination; Male; MAP Kinase Signaling System; Os	2015
Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets. Vascular pharmacology, 2016, Volume: 76 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Case-Control Studies	2016
Parathyroid hormone(1-34) exhibits more comprehensive effects than celecoxib in cartilage metabolism and maintaining subchondral bone micro-architecture in meniscectomized guinea pigs. Osteoarthritis and cartilage, 2016, Volume: 24, Issue:6 Topics: Animals; Architecture; Cartilage; Celecoxib; Guinea Pigs; Male; Osteoarthritis; Parathyroid Hormone	2016
Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection. Journal of controlled release : official journal of the Controlled Release Society, 2016, 12-28, Volume: 244, Issue:Pt A Topics: Animals; Celecoxib; Cell Differentiation; Cell Survival; Cyclooxygenase 2 Inhibitors; Drug Delivery	2016
Imprecision: Limitations to Interpretation of a Large Randomized Clinical Trial. Circulation, 2017, 01-10, Volume: 135, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi	2017
Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen. Nature reviews. Rheumatology, 2017, Volume: 13, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Clinical Trials as Topic;	2017
[Articular cartilage in osteoarthritic patients: effects of diclofenac, celecoxib and glucosamine sulfate on inflammatory markers]. Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), 2007, Volume: 64, Issue:2 Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cartilage, Articula	2007
Protective effects of butanol fraction from Betula platyphyla var. japonica on cartilage alterations in a rabbit collagenase-induced osteoarthritis. Journal of ethnopharmacology, 2009, Jun-25, Volume: 123, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Betula; Cartilage, Articular; Celecoxib; Collagenases; Cyclooxyge	2009
Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. Journal of medical economics, 2009, Volume: 12, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec	2009
NSAIDs and risk of lower gastrointestinal bleeding. Lancet (London, England), 2010, Jul-17, Volume: 376, Issue:9736 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Coloni	2010
The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo. Journal of ethnopharmacology, 2010, Sep-15, Volume: 131, Issue:2 Topics: Analgesics; Anemarrhena; Animals; Anti-Inflammatory Agents; Behavior, Animal; Capillary Permeability	2010
Gait analysis and pain response of two rodent models of osteoarthritis. Pharmacology, biochemistry, and behavior, 2011, Volume: 97, Issue:3 Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Gait; Male; Neuropeptides;	2011
Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis. Current medical research and opinion, 2011, Volume: 27, Issue:2 Topics: Adult; Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib;	2011
Effect of Phellodendron amurense in protecting human osteoarthritic cartilage and chondrocytes. Journal of ethnopharmacology, 2011, Mar-24, Volume: 134, Issue:2 Topics: ADAM Proteins; ADAMTS4 Protein; Cartilage, Articular; Celecoxib; Cells, Cultured; Chondrocytes; Coll	2011
The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model. Rheumatology international, 2012, Volume: 32, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Chondrocytes; Col	2012
Impact of Celecoxib restrictions in medicare beneficiaries with arthritis. The American journal of managed care, 2011, Volume: 17, Issue:7 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib;	2011
Lack of a chondroprotective effect of cyclooxygenase 2 inhibition in a surgically induced model of osteoarthritis in mice. Arthritis and rheumatism, 2012, Volume: 64, Issue:1 Topics: Administration, Oral; Animals; Arthritis, Experimental; Arthroplasty, Replacement, Knee; Cartilage,	2012
Changing the outcome of osteoarthritis: still a challenge for cyclooxygenase 2 inhibitors. Arthritis and rheumatism, 2012, Volume: 64, Issue:1 Topics: Animals; Arthritis, Experimental; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Male; Oste	2012
Comparison and validation of data-mining indices for signal detection: using the Korean national health insurance claims database. Pharmacoepidemiology and drug safety, 2011, Volume: 20, Issue:12 Topics: Adverse Drug Reaction Reporting Systems; Aged; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 2	2011
The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial. Journal of medical economics, 2012, Volume: 15, Issue:3 Topics: Advisory Committees; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis	2012
Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte. Medical science monitor : international medical journal of experimental and clinical research, 2012, Volume: 18, Issue:6 Topics: Animals; Apoptosis; Cartilage, Articular; Celecoxib; Chondrocytes; Collagen Type II; Cyclooxygenase	2012
Silymarin potentiates the anti-inflammatory effects of Celecoxib on chemically induced osteoarthritis in rats. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2012, Oct-15, Volume: 19, Issue:13 Topics: Animals; Antioxidants; Cartilage, Articular; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Evaluation	2012
Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. NeuroImage, 2013, Jan-01, Volume: 64 Topics: Action Potentials; Animals; Brain; Celecoxib; Disease Models, Animal; Humans; Male; Nerve Net; Osteo	2013
Augmented chondroprotective effect of coadministration of celecoxib and rebamipide in the monosodium iodoacetate rat model of osteoarthritis. Archives of pharmacal research, 2013, Volume: 36, Issue:1 Topics: Administration, Oral; Alanine; Animals; Arthritis, Experimental; Behavior, Animal; Cartilage; Celeco	2013
Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. Clinical therapeutics, 2002, Volume: 24, Issue:6 Topics: Celecoxib; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Diuretics; Edema; Humans; Hypertensio	2002
[Coxib spares the stomach. This is true also for patients with preventive aspirin administration]. MMW Fortschritte der Medizin, 2002, May-16, Volume: 144, Issue:20 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Drug Therapy, Co	2002
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Jun-25, Volume: 166, Issue:13 Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardi	2002
Robin goodfellow. Rheumatology (Oxford, England), 2002, Volume: 41, Issue:9 Topics: Antibodies, Monoclonal; Antirheumatic Agents; Celecoxib; Clinical Trials as Topic; Humans; Inflixima	2002
[Mobility and quality of life for arthrosis and rheumatism patients. Modern pain management with selective cox-2 inhibition]. MMW Fortschritte der Medizin, 2002, Jul-26, Volume: 144, Issue:29-30 Topics: Activities of Daily Living; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxi	2002
Toxic epidermal necrolysis after celecoxib therapy. Pharmacotherapy, 2002, Volume: 22, Issue:9 Topics: Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Osteoarthritis; Pyraz	2002
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. The American journal of managed care, 2002, Volume: 8, Issue:15 Suppl Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cross-Sectional S	2002
Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Nov-12, Volume: 167, Issue:10 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibito	2002
A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. British journal of clinical pharmacology, 2002, Volume: 54, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cycl	2002
Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cele	2002
COX-2 inhibitors: new drugs for the management of pain and inflammation. Dentistry today, 2001, Volume: 20, Issue:2 Topics: Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid	2001
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity. BMJ (Clinical research ed.), 2003, Feb-08, Volume: 326, Issue:7384 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Data Interpretation, Stat	2003
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated. BMJ (Clinical research ed.), 2003, Feb-08, Volume: 326, Issue:7384 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Gastrointestinal Diseases	2003
Celecoxib-induced upper gastrointestinal hemorrhage and ulceration. Southern medical journal, 2002, Volume: 95, Issue:12 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Duodenal Ulcer;	2002
Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. Clinical nephrology, 2003, Volume: 59, Issue:2 Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Fema	2003
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clinical therapeutics, 2003, Volume: 25, Issue:1 Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D	2003
No success with the SUCCESS trial. The American journal of cardiology, 2003, Apr-01, Volume: 91, Issue:7 Topics: Abbreviations as Topic; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib;	2003
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart]. MMW Fortschritte der Medizin, 2003, Mar-13, Volume: 145, Issue:11 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu	2003
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis. The American journal of cardiology, 2003, May-15, Volume: 91, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cycloox	2003
A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. Clinical therapeutics, 2003, Volume: 25, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Costs and Cost Analysis; C	2003
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis. Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben	2003
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and rheumatism, 2003, Jun-15, Volume: 49, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Canada; Cel	2003
Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford, England), 2003, Volume: 42, Issue:11 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N	2003
Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford, England), 2003, Volume: 42, Issue:11 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cele	2003
Drug utilization review of celecoxib in Ontario. Rheumatology (Oxford, England), 2003, Volume: 42 Suppl 3 Topics: Aged; Arthritis, Rheumatoid; Celecoxib; Cost Control; Cyclooxygenase Inhibitors; Drug Utilization Re	2003
Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. The Journal of rheumatology, 2003, Volume: 30, Issue:11 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Diclofenac; Dose-Res	2003
Aseptic meningitis possibly associated with celecoxib. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Female; Humans; Meningitis, Aseptic; Osteo	2004
An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clinical therapeutics, 2003, Volume: 25, Issue:12 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi	2003
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. The Journal of rheumatology, 2004, Volume: 31, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services	2004
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiology and drug safety, 2004, Volume: 13, Issue:5 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inh	2004
[Celecoxib in the symptomatic treatment of active osteo- or rheumatoid arthritis. Results of a post-marketing surveillance]. Deutsche medizinische Wochenschrift (1946), 2004, May-21, Volume: 129, Issue:21 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors	2004
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. The Journal of rheumatology, 2004, Volume: 31, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecox	2004
Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint bone spine, 2004, Volume: 71, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi	2004
Hypertension associated with therapies to treat arthritis and pain. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent	2004
Relationship between COX-2 specific inhibitors and hypertension. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:2 Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Hum	2004
Celecoxib-induced methemoglobinemia. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:10 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Male; Methemoglobinemia; Osteoarth	2004
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid]. MMW Fortschritte der Medizin, 2004, Apr-08, Volume: 146, Issue:15 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib;	2004
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; C	2005
Selective COX-2 inhibitor regulates the MAP kinase signaling pathway in human osteoarthritic chondrocytes after induction of nitric oxide. International journal of molecular medicine, 2005, Volume: 15, Issue:2 Topics: Annexin A5; Apoptosis; Blotting, Western; Cartilage; Celecoxib; Cell Separation; Chondrocytes; Cultu	2005
A tale of two coxibs. JAAPA : official journal of the American Academy of Physician Assistants, 2005, Volume: 18, Issue:3 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Product Surveillance, Postma	2005
Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis and cartilage, 2005, Volume: 13, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; C	2005
[Role of prostaglandins in the pathogenesis of stomach ulcer and gastropathy caused by non-steroid anti-inflammatory drugs]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2005, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female;	2005
Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis. Rheumatology (Oxford, England), 2006, Volume: 45, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Cyclooxygenase 2;	2006
Clinical Questions #6. Does celecoxib increase cardiovascular risk? WMJ : official publication of the State Medical Society of Wisconsin, 2005, Volume: 104, Issue:8 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Evidence-Based Medicine; Female; Hu	2005
Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints. Rheumatology international, 2006, Volume: 26, Issue:11 Topics: Animals; Anterior Cruciate Ligament; Celecoxib; Cells, Cultured; Chondrocytes; Cyclooxygenase Inhibi	2006
Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? Arthritis and rheumatism, 2006, Feb-15, Volume: 55, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Costs and Cost Analysi	2006
Glucosamine & chondroitin use questioned in mild cases. Drug combo benefits moderate-to-severe knee osteoarthritis, but not so with lesser cases. Health news (Waltham, Mass.), 2006, Volume: 12, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin; Dietary Supplements; Glucosamine; H	2006
Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone. British journal of clinical pharmacology, 2006, Volume: 61, Issue:4 Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inh	2006
Arthritis supplement combination falls short in study. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, Apr-01, Volume: 63, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chondroitin Sulfates; Clinical Trials as Topic;	2006
Eosinophilic fasciitis in a 57-year-old Japanese-American woman. Hawaii medical journal, 2007, Volume: 66, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diagnosis, Differential; Eosinophilia; Fasciitis	2007
An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC gastroenterology, 2007, Jul-04, Volume: 7 Topics: Age Factors; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit	2007
COX-2 inhibitor. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:10 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Osteoarthritis; Pyrazoles; Pyridines; Ra	2007
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coh	2008
Celecoxib for arthritis. The Medical letter on drugs and therapeutics, 1999, Jan-29, Volume: 41, Issue:1045 Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyg	1999
Celecoxib approved as NSAID with some concessions on class warning. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Mar-01, Volume: 56, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors	1999
New drug overview. Celecoxib. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, May-15, Volume: 56, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Osteoarthritis; Pyrazoles	1999
Celecoxib: a COX-2 inhibitor. The American journal of managed care, 1999, Volume: 5, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic;	1999
COX-2 inhibitors. Magic bullets or merely mortal? Harvard health letter, 2000, Volume: 25, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox	2000
The cox-2 inhibitors. Journal of the Massachusetts Dental Society, 1999,Fall, Volume: 48, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C	1999
Acute onset of auditory hallucinations after initiation of celecoxib therapy. The American journal of psychiatry, 2000, Volume: 157, Issue:6 Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors;	2000
COX-2 inhibitors. The Medical journal of Australia, 2000, Oct-16, Volume: 173, Issue:8 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenas	2000
Allergic skin reaction to celecoxib. Dermatology (Basel, Switzerland), 2000, Volume: 201, Issue:4 Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Drug Eruptions; Female; Humans; Male; Middle Aged; Osteo	2000
Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology (Oxford, England), 2000, Volume: 39 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost of Illness; Cost-Ben	2000
The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford, England), 2000, Volume: 39 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost of Illness; Cost-Ben	2000
Selective COX-2 inhibitors. The American journal of nursing, 2001, Volume: 101, Issue:4 Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib;	2001
Acute renal failure related to high-dose celecoxib. Annals of internal medicine, 2001, Jul-03, Volume: 135, Issue:1 Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dose-Response Relationship,	2001
[Role of cyclooxygenase-2 (COG-2) in the etiology of pain]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit	2001
[Gastroduodenal tolerance of celecoxib (celebrex) in patients with osteoarthrosis: an endoscopic evaluation]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Duodenum; Endoscopy,	2001
Arthritis: what it is, why you get it and how to stop the pain. Newsweek, 2001, Sep-03, Volume: 138, Issue:10 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Celecoxib; Cyclooxy	2001
Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. JAMA, 2002, Apr-10, Volume: 287, Issue:14 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cycloox	2002
Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. JAMA, 2002, Apr-10, Volume: 287, Issue:14 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cycloox	2002
[Symptomatic therapy of arthrosis and rheumatoid arthritis. Who will benefit from Coxib?]. MMW Fortschritte der Medizin, 2002, Apr-04, Volume: 144, Issue:14 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Humans; Middle Aged	2002
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr The Journal of rheumatology, 2002, Volume: 29, Issue:5 Topics: Aged; Arthritis, Rheumatoid; Bias; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2;	2002
Selective COX-2 inhibition. Bulletin on the rheumatic diseases, 1999, Volume: 48, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors	1999
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ (Clinical research ed.), 2002, Jun-01, Volume: 324, Issue:7349 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase	2002

Intervention	Percentage of participants (Number)
	PPIs	H2RAs	Gastric protective agents
Celecoxib	23.0	5.0	0.9
nsNSAIDs	24.2	5.7	1.0

celecoxib and Osteoarthritis

Research Excerpts

Research

Studies (243)

Authors

Clinical Trials (22)

Trial Overview

Trial Outcomes

Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time Curve From Zero to Infinity (AUC 0-∞) of Single Dose LY3127760

PK: Area Under the Concentration Versus Time Curve During One Dosing Interval [AUC-tau (τ)] of Multiple Doses LY3127760

PK: Cmax of Multiple Doses LY3127760

PK: Maximum Observed Concentration (Cmax) of Single Dose LY3127760

PK: Time of Maximum Observed Concentration (Tmax) of Single Dose LY3127760

PK: Tmax of Multiple Doses LY3127760

Change From Baseline in Patient's Assessment of Arthritis Pain (VAS)

The First Occurrence of a Major Adverse Cardiovascular Events (MACE)

The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC).

The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE)

Dose-dependent Differences in the BOLD Response to fMRI Tasks in the Amygdala

Change From Baseline in C-Reactive Protein to Month 6/ET

Change From Baseline in Ferretin to Month 6/ET

Change From Baseline in Hematocrit at Month 6/ET

Change From Baseline in Hemoglobin at Month 6/ET

Change From Baseline in Iron Binding Capacity to Month 6/ET

Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET)

Number of Subjects Alive at the Post Trial Interview

Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview

Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin

Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)

Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)

Number of Subjects With Moderate to Severe Abdominal Symptoms

Number of Subjects With SUs

Number of Subjects Withdrawn Due to GI Adverse Events (AEs)

Change From Baseline in Hepatic Measures of GGT, AST or ALT to Month 6/ET

Number of Subjects With CSULGIEs by History of GD Ulceration

Number of Subjects With Hepatic AEs in Gamma Glutamyl-Transferase (GGT), Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) of 3 Times the Upper Limit of Normal (ULN)

Change From Baseline Hb at Week 24

Change From Baseline Hct at Week 24

Hematocrit (Hct) at Baseline

Hemoglobin (Hb) at Baseline

Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs)

Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)

Percentage of Participants With Moderate to Severe Abdominal Symptoms

Percentage of Participants With Positive Blood Fecal Occult

Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Amount of Pain Relief

Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Duration of Pain Relief

Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Time to Pain Relief

Percentage of Participants Satisfied With Efficacy of Current Pain Medication Overall

Percentage of Participants With Clinically Significant Decrease in Hct and/or Hb From Baseline

Percentage of Participants With Non-study Medication Utilization

Percentage of Participants With Proton Pump Inhibitor (PPI) and Other Gastric Protective Drug Utilization

Reviews

Trials

Other Studies